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Abstract

Multilevel analysis of individual, neighborhood, and health care facility characteristics associated with
achievement and maintenance of HIV viral suppression among persons newly diagnosed with HIV in New
York City
By
Ellen Weiss Wiewel
Adviser: Professor Luisa N. Borrell
Objective
To investigate the effect of individual, health care facility, and neighborhood characteristics on
achievement and maintenance of HIV viral suppression, among New York City residents aged 13 years
and older diagnosed with HIV between 2006 and 2012.
Methods
I used individual-level data from the New York City HIV surveillance registry and Case
Surveillance-Based Sampling, facility-level data from the surveillance registry, and neighborhood-level
data from the U.S. Census and American Community Survey. The outcomes of interest were first viral
suppression after diagnosis (Aims 1 and 3; ≤400 copies/mL) and virologic failure after first suppression
among persons who achieved suppression (Aim 2; viral load ≥1,000 copies/mL or no viral load test for 12
consecutive months). Aim 3 was limited to persons interviewed for Case Surveillance-Based
Sampling. Multivariable proportional hazards regressions were used to assess the likelihood of
suppression or failure for individual, facility, and neighborhood characteristics, accounting in Aims 1 and 2
for clustering of outcomes.
Results
Of 12,547 persons newly diagnosed with HIV in 2006–2010, 44% achieved suppression within 12
months of diagnosis. In adjusted analyses, persons 13-49 years old, men, blacks and Hispanics, USborn, heterosexuals, and persons diagnosed in 2006 and 2008 were less likely to achieve suppression
than persons 60 years old and older, women, whites, foreign-born, men who have sex with men, and
persons diagnosed in 2010, respectively. Suppression rates were also lower among persons who were
iv

not eligible for treatment, or who were diagnosed at facilities that diagnosed 10-74 patients per year, were
screening/diagnosis/referral sites, or within one mile of the person’s home. No neighborhood factors
were associated with suppression. Out of 8,927 persons newly diagnosed with HIV in 2006–2010 who
achieved viral suppression, 18.2% experienced virologic failure within 12 months of suppression. After
adjustment, the following groups were the least likely to maintain suppression: younger persons (<50
years old vs. ≥60), blacks and Hispanics, US- and US-dependency born persons, heterosexuals and
injection drug users, persons with CD4 counts ≥500 cells/mL at suppression, persons receiving care at
facilities that were not large outpatient facilities or large private practices, and residents of high- or veryhigh-poverty neighborhoods. Suppression within 12 months of diagnosis was achieved by 65% of
persons newly diagnosed with HIV in 2006–2012 and interviewed by Case Surveillance-Based Sampling
(n=92). Perceived neighborhood social cohesion was not associated with suppression.
Conclusions
Persons who were younger, black or Hispanic, US-born, heterosexual, diagnosed in earlier years,
not treatment-eligible, living within one mile of their health care facility, diagnosed or cared for at certain
types of facilities such as those with fewer HIV-positive patients, and living in a higher-poverty
neighborhood were less likely to achieve and/or maintain suppression. Assistance with post-diagnosis
linkage to and retention in care, ART prescribing, or adherence that is targeted to groups with
characteristics associated with poorer outcomes may improve achievement and maintenance of viral
suppression in New York City.
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Chapter 1. Introduction
HIV and viral suppression in the US and NYC
New York City (NYC) is home to more than 7% of all persons newly diagnosed with HIV in the
United States (US) each year.[1, 2] It is recommended that persons newly diagnosed with HIV have their
viral load (VL) measured as soon as they begin HIV-related medical care and then at least every six
months.[3] Acute HIV infection typically is accompanied by very high VL (e.g., >100,000 copies of HIV
ribonucleic acid, RNA, per milliliter, mL, of blood) which eventually declines to a lower set point that varies
by individual. Reduction to low or undetectable levels (e.g., ≤400 copies/mL) is called viral suppression
and is typically achieved through treatment with antiretroviral therapy (ART).[4] Because of
improvements in ART since the mid-1990s, and recommendations that ART should be initiated before
persons with HIV become immunocompromised, HIV has been transformed from an almost inevitably
fatal disease to a chronic, manageable condition. In addition, because of these changes, viral
suppression has become more common than virologic failure (i.e., when VL becomes detectable or
reaches a high level), among persons living with HIV or acquired immunodeficiency syndrome (AIDS;
PLWHA). Provided that the virus is sensitive to the multi-drug regimen chosen and the person is
adherent, ART suppresses virus quickly (within 24 weeks) and durably.[5, 6] Achievement and
maintenance of viral suppression, and avoidance of virologic failure, slows progression of HIV disease,[7]
and reduces the likelihood of onward sexual transmission.[8] The 2015 goal of the US National HIV/AIDS
Strategy is a 20% increase in the proportion of persons virally suppressed within three of the populations
most affected by HIV (blacks, Hispanics, and gay and bisexual men).[9] As few as 20% of PLWHA were
thought to be suppressed in the US in the early 2000s, while today most estimates exceed 50%;[10-14] in
NYC, it was 59% in 2010.[14] During 2006-2009, suppression within 12 months of HIV diagnosis in NYC
increased from 36% to 45%, and maintenance of suppression for 12 months increased over the same
period from 79% to 86%.[15]

Summary of the literature and current gaps in knowledge
Epidemiologic literature has explored factors related to viral suppression and virologic failure
among persons with HIV. However, studies have rarely examined VL over time or in terms of factors
1

other than individual demographics and clinical characteristics.[15, 16] With respect to time
measurement, most published population-level VL statistics, including those with the recent focus on the
HIV care continuum, refer only to the most recent VL.[10, 13] A single VL may indicate neither
maintenance of suppression (also referred to as sustained suppression) nor virologic failure.[16] The few
population-based studies following persons’ viral loads over time have found that substantial proportions
of those achieving suppression do not maintain it.[15, 17-19] For example, among newly diagnosed New
Yorkers achieving suppression, 18% experienced virologic failure within 12 months.[15] I measured time
from HIV diagnosis to first viral suppression and time from first suppression to virologic failure, with a
follow-up time of up to seven years.
More rapid achievement of suppression, longer maintenance of suppression, and lower failure
rates have been associated with individual-level demographic characteristics including older age,[13, 15,
20] male sex,[15, 21-23] non-black race,[13, 15, 24-28] baseline clinical status indicators such as CD4
count and VL,[15, 29, 30], and more recent calendar year of diagnosis.[15] For example, in the CDC’s
Medical Monitoring Project, among persons with HIV on ART, 79% of males achieved suppression as
compared with 71% of females.[13] An analysis among newly diagnosed residents of Seattle and
surrounding King County found that blacks had 15% decreased odds of suppression compared with
whites, while Hispanics had similar odds as whites.[25]
Studies of achievement and maintenance of suppression may further benefit from the addition of
variables describing characteristics of health care facilities where people are diagnosed and receive care
as well as neighborhoods where people live. For example, facility characteristics, such as type of clinical
setting, accessibility including travel distance, support services offered, and physician experience have
been shown to influence intermediary health outcomes among persons with HIV, including receipt of and
adherence to ART, both necessary steps for maintenance of viral suppression.[31-35] Specifically, a
large sample of US hospitals found lower mortality for patients in dedicated AIDS units relative to those in
hospitals without these units.[36] Studies in developing countries have found that clinic distance from
patient residence influences linkage to care, an important precursor to viral suppression.[37] I am not
aware of studies examining the effect of facility distance on HIV-related outcomes entirely within a large
city in an industrialized nation.
2

Neighborhood factors such as lower area-level socioeconomic status have been associated with
higher rates of diagnosis of HIV or AIDS, delayed care and treatment, and increased mortality.[31, 33, 3843] Additionally, lower perceived neighborhood social cohesion has been associated with lower primary
care use among older urban adults[44] as well as lower condom use and higher STI rates among urban
adolescents and young adults[45, 46]. The latter factors (condom use and STI rates) have the potential to
influence the time from HIV diagnosis to viral suppression. More broadly, public health researchers have
characterized social and structural factors, such as individual- and neighborhood-level poverty, as
fundamental drivers of health disparities and encouraged the inclusion of such broader factors in
epidemiologic analyses.[47-50] For example, the Alameda County Study was one of the first
epidemiologic studies to identify an effect of area-level factors on individual health, and it did so in a
general population, not a population of persons with HIV: individual mortality risk was found to be higher
among persons living in high-poverty areas than low-poverty areas, even after controlling for factors
including individual income.[51] However, few studies on virologic suppression or failure have examined
facility or neighborhood characteristics.[31-34] I assessed the impact of facility and neighborhood
characteristics on the achievement and maintenance of viral suppression while controlling for individual
characteristics.
Individual and facility characteristics associated with achievement and maintenance of viral
suppression can now be measured by many HIV surveillance registries[15, 25, 52] and will become
increasingly important as more persons with HIV receive ART and achieve suppression. Area-level data
aggregated from individual responses to national data sources, such as the US Census and the American
Community Survey (ACS), can supplement surveillance data with neighborhood-level variables, and can
be matched to individual-level surveillance data by patient residence. I linked data from the US Census
and ACS with data from the HIV surveillance registry to conduct these analyses.

Overview of the dissertation
Overall goals
I investigated the effect of individual, health care facility, and neighborhood characteristics on the
achievement and maintenance of HIV viral suppression, among New York City residents aged 13 years
3

and older who were diagnosed with HIV between 2006 and 2012. The results may be used to improve
public health by identifying groups of persons with lower rates of achievement or maintenance of viral
suppression who might benefit from interventions to improve ART initiation and adherence.
Specific aims
The following specific aims were addressed:
AIM 1: Examine the independent effects of individual-, neighborhood- and health care facility-level
characteristics on HIV viral suppression, among adults and adolescents in New York City who were newly
diagnosed with HIV between 2006 and 2010.
AIM 2: Examine the independent effects of individual-, neighborhood- and health care facility-level
characteristics on HIV virologic failure, among adults and adolescents in New York City who were newly
diagnosed with HIV between 2006 and 2010.
AIM 3 (exploratory aim): Examine the independent effect of perceived neighborhood social cohesion on
HIV viral suppression, among adults in New York City who were newly diagnosed with HIV between 2006
and 2012.
Organization of the dissertation
Following this introduction, the dissertation contains four additional chapters. Chapter 2 assesses
the individual, facility, and neighborhood factors associated with achievement of viral suppression after
diagnosis among New Yorkers newly diagnosed with HIV in 2006-2010 (Aim 1). Chapter 3 begins with
the subset of persons from the previous aim who achieved viral suppression and assesses the individual,
facility, and neighborhood factors associated with maintenance of viral suppression (Aim 2). Chapter 4
assesses individual and neighborhood factors, including perceived neighborhood social cohesion,
associated with achievement of viral suppression after diagnosis, among a sample of New Yorkers newly
diagnosed with HIV in 2006-2012 (Aim 3). Chapter 5 summarizes findings from aims 1-3 and discusses
limitations and strengths of the analyses. Finally, I conclude with policy implications and directions for
future research.
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Data sources
In this dissertation, I used individual-level data from the NYC HIV surveillance registry and Case
Surveillance-Based Sampling,[53] facility-level data from the registry, and Census-tract- and ZIP-codelevel data from the 2010 US Census[54] and the 2011 American Community Survey.[55] The
surveillance registry includes all persons diagnosed with HIV and reported in NYC since 2000 and all
persons with AIDS since 1981. It gathers information by medical record review, provider report at
diagnosis, personal interviews with patients, and HIV-related laboratory tests, which are electronically
reported to surveillance for all newly confirmed and existing cases. With respect to first HIV/AIDS
diagnosis date, the concordance of surveillance data with medical records is high (84% of NYC AIDS
patients identified via medical record had been reported to the surveillance registry) and with self-report
somewhat high (56% of US HIV surveillance-self-report pairs had the same year of diagnosis, and 30% of
self-reported dates were an earlier year).[56-58] Surveillance data are also timely, with reportable events
typically confirmed and appearing in the registry within several months.[57]
The surveillance registry includes individual-level demographic and clinical information collected
at the time of first report of HIV diagnosis (Aims 1 and 3) or first VL test indicating suppression (Aim 2),
address of residence at diagnosis, and HIV-related laboratory test results from 2006-2012 for all New
Yorkers newly diagnosed with HIV. Laboratory reports contain the test type, specimen collection date,
result, and submitting provider or facility. Health care facility data from 2006-2012 were obtained from the
registry and linked to cases according to the facility diagnosing the patient (Aims 1 and 3) or that
conducted the first VL test indicating suppression for each case (Aim 2). Finally, neighborhood data were
acquired from the 2010 US Census and the 2011 American Community Survey 5-year estimates. Place
of residence was geocoded, and neighborhood data was linked to cases through patient residence at the
Census tract level (Aims 1 and 2) or ZIP code level (Aim 3). Case Surveillance-Based Sampling was
used for Aim 3, including the main questionnaire of the project and three local, scaled questions about
whether people in the patient’s neighborhood of residence were trustworthy, close-knit, or willing to help
neighbors. Answers to these three questions were combined to create a composite measure of
perceived neighborhood social cohesion.[45]

5

Outcomes
The outcomes of interest were first viral suppression after diagnosis (Aims 1 and 3) and failure
after first suppression (Aim 2). The cut-off for suppression in all three aims was 400 copies/mL because
this was the highest (i.e., least-sensitive) lower detectable limit of all VL assays used during the study
period.[59] In Aim 2, virologic failure was defined as having a VL ≥1,000 copies/mL or not having any VL
test for 12 consecutive months. The 1,000-copy cutoff permitted a temporary blip that would not
necessarily signal virologic failure since VL changes easily,[60] and risk of HIV transmission from a
person with a VL under 1,000 copies/mL is almost nonexistent.[8, 61] Requiring VL tests every 12
months in order to be considered as maintaining suppression ensured at least minimal engagement in
care and provided an endpoint for persons who dropped out of care, since care was required to detect
any VL and it was unreasonable to assume that persons who dropped out of care in NYC would remain
suppressed. The follow-up period for Aims 1 and 2 ended on 12/31/2012 and for Aim 3 on 6/30/2014.

Study population
Our analysis population was drawn from NYC residents who were newly diagnosed with HIV
between 2006 and 2010 (Aims 1 and 2) or between 2006 and 2012 (Aim 3) and were at least 13 or 18
years of age at diagnosis (Aims 1 and 3, respectively) or at least 13 at suppression (Aim 2). Aim 2 was
limited to the subset of these persons who achieved viral suppression (≤400 copies/mL) ≥31 days
following diagnosis and by 12/31/2012. Aim 3 assessed viral suppression for a much smaller population
(hence its exploratory nature), because it drew from a survey of persons sampled from new diagnoses
through 2012. These persons’ addresses were not geocoded to XY coordinates, so neighborhood-level
variables were constructed at the level of ZIP code.
Persons were excluded from the analysis population if their death date appeared to precede their
first diagnosis (Aims 1 and 3) or suppression date (Aim 2), their date of HIV diagnosis or viral suppression
was potentially misclassified, information about address or neighborhood of residence and facility of
diagnosis or suppression was missing, or their address data indicated that they were homeless or
institutionalized. These exclusions yielded an analytic sample of 12,547 persons in Aim 1, 8,927 persons
in Aim 2, and 92 persons in Aim 3 (see Appendix 1 and Appendix 2).
6

Statistical analysis
Descriptive statistics were calculated for selected characteristics at the individual, health care
facility, and neighborhood levels and presented for the overall population and according to viral
suppression status (Aims 1 and 3) or virologic failure status (Aim 2) within 12 months of diagnosis. The
association between each variable and virologic suppression or failure within 12 months was estimated
using Chi-square statistics; differences in median days to suppression or failure were assessed using the
Mann-Whitney U test.
Kaplan-Meier curves showing the number of days from diagnosis to suppression (Aims 1 and 3)
or suppression to failure (Aim 2) were generated for key individual, health care facility, and neighborhood
characteristics; log-rank tests were used to assess differences between groups.
Cox proportional hazards regressions estimated the association of individual, facility, and
neighborhood-level factors with suppression (Aims 1 and 3) or failure (Aim 2) in crude and adjusted
models. When the analytic sample was sufficiently large (Aims 1 and 2), these regressions were
multilevel. Specifically, robust sandwich estimation of the standard errors was used to account for
correlations of individual outcomes clustered within either facility or neighborhood (Census tract).[62, 63]
After estimating unadjusted rates for suppression (Aims 1 and 3) or failure (Aim 2) for each individual,
facility, and neighborhood characteristic, models were fitted to estimate the hazards of virologic
suppression or failure for each characteristic, after adjustment for other characteristics.
Previous epidemiologic studies of viral suppression have often used survival analysis as their
methodology.[15, 29, 64, 65] This time-to-event technique is useful for measuring the amount of time
between HIV diagnosis and first achievement of viral suppression. It can also be used to measure the
amount of time that suppression is maintained after it is achieved, i.e., until virologic failure. Survival
analysis also permits persons to be in the analysis for only part of the study period, even if they enter it
after the start date (e.g., they are newly diagnosed with HIV during the follow-up period) or leave before
the end date (e.g., they are lost to follow-up before they have the outcome of interest). The multilevel
models in Aims 1 and 2 permitted examination of the influence of social and structural (i.e., neighborhood
and facility) factors and of potential mechanisms by which individual factors such as race/ethnicity might
be associated with suppression.
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Applications of findings
The findings of these analyses may be valuable to agencies planning testing programs, medical
care for individuals with HIV, and “prevention with positives” programs. They may also help strengthen
existing programs, such as the NYC care coordination program and housing services, which appear to be
working,[66, 67] or help explain why other programs may not be working. Findings about neighborhood
characteristics associated with shorter time to suppression and longer maintenance of suppression could
identify geographic groups of persons in need of additional services. They might also influence future
assessments of areas that could benefit from subsidized and/or supportive housing for persons with HIV.
Health care facility characteristics associated with shorter time to suppression and longer maintenance of
suppression could be examined for their “best practices” and these practices considered either for scaleup across facilities or in recommendations of which types of facilities have the potential to provide the
best care. Further analyses could assess how populations with long-term detectable VLs could be
offered greater support via facility- and neighborhood-level changes, or how HIV care and services
generally could be structured to maximize (a) the linkage of persons with HIV to facilities that have
successfully helped patients like them achieve and maintain suppression and (b) the housing of persons
with HIV in neighborhoods or other communities with suppression-supporting characteristics.

Ethical considerations
Ethical approval for these analyses was provided by the Institutional Review Boards of Lehman
College of the City University of New York and of the New York City Department of Health and Mental
Hygiene. Maintenance of confidentiality and privacy of person-level information was a top priority
throughout the research process. Among other protections, all person-level data were maintained on
computer servers of the New York City Department of Health and Mental Hygiene and analyzed in the
Department’s HIV Epidemiology and Field Services Program, which conducts HIV surveillance and has
numerous facility, technical, electronic, and procedural safeguards to promote security and minimize
opportunities for breaches. The doctoral student underwent confidentiality training at the Department,
passed the Basic Course for social and behavioral research with human subjects via the Collaborative
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Institutional Training Initiative (CITI), and had over 10 years of professional experience working with data
in the HIV Epidemiology and Field Services Program, which conducts HIV surveillance.
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Chapter 2. Multilevel analysis of individual, health care facility, and neighborhood
characteristics associated with achievement of HIV viral suppression among
persons newly diagnosed with HIV in New York City
Introduction
New York City (NYC) is home to more than 7% of all persons newly diagnosed with HIV in the
United States (US) each year.[1, 2]. It is recommended that persons newly diagnosed with HIV have their
viral load (VL) measured as soon as they begin HIV-related medical care and then at least every six
months.[3] Acute HIV infection typically is followed by a very high VL (e.g., >100,000 copies of HIV RNA
per milliliter of blood) which eventually declines to lower levels that vary by individual. Further reduction
of HIV VL to low or undetectable levels (e.g., ≤400 copies/mL) is referred to as viral suppression.
Although a small percentage of persons (i.e., “elite controllers") is able to achieve suppression without
treatment, most persons achieve suppression through treatment with antiretroviral therapy (ART).[4]
Provided that the virus is sensitive to the multi-drug regimen chosen and the person is adherent,
suppression is achieved quickly (within 24 weeks) and durably.[5, 6]
Viral suppression not only slows progression of HIV disease [7] but also reduces the likelihood of
onward sexual transmission.[8] As few as 20% of PLWHA were thought to be suppressed in the US in
the early 2000s, while today most estimates exceed 50%;[10-14] in NYC, it was 59% in 2010.[14] In
2010, the US National HIV/AIDS Strategy set as a goal a 20% increase by 2015 in the proportion of
persons in populations most affected by HIV (blacks, Hispanics, and gay and bisexual men) who are
virally suppressed.[9]
Although retention in care and ART are the main drivers of viral suppression, more rapid
achievement of suppression has also been associated with individual-level demographic characteristics
(e.g., older age,[13, 15, 20] male sex,[21-23] and non-black racial/ethnic category [13, 24-28]), and
baseline clinical status indicators (e.g, CD4 count and VL[15, 29, 30]).
Studies focusing on individual-level factors affecting viral suppression may benefit from the
addition of variables describing characteristics of health care facilities in which people are diagnosed, as
these characteristics have been shown to influence intermediary health outcomes among persons with
HIV.[31-33] For example, facility-level characteristics have been associated with linkage to care after
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diagnosis,[35] receipt of ART,[33, 34] and adherence to treatment, all necessary steps toward viral
suppression.[32] The type of clinical setting and accessibility of a medical facility including travel distance
for patients, as well as the support it offers its patients, can affect adherence.[32] Few studies on viral
suppression, however, have included these facility characteristics.[31-33]
Similarly, the relationship between neighborhood-level socioeconomic characteristics and viral
suppression has rarely been studied. Lower socioeconomic status has been associated with higher rates
of diagnosis of HIV or AIDS, delayed access to treatment, and mortality.[31, 33, 38-43] For example, in a
US city, HIV-positive residents of higher-unemployment neighborhoods were less likely to be on ART.[43]
Even in a province of Canada, a country with universal health care and free HIV treatment, after
controlling for clinical characteristics, it was found that residents of lower-SES neighborhoods (as
measured by median income) were less likely than residents of higher-SES neighborhoods to be
prescribed the ART regimen that was the standard of care.[33] We therefore investigated the effect of
individual, health care facility, and neighborhood characteristics on achievement of viral suppression,
among NYC residents ≥13 years of age who were diagnosed with HIV between 2006 and 2010, before
and after controlling for selected characteristics.

Methods
Data sources
This retrospective analysis used data from the NYC HIV surveillance registry, the 2010 US
Census,[54] and the 2011 American Community Survey.[55] The surveillance registry includes all
persons diagnosed and reported with AIDS in NYC since 1981 and HIV since 2000. It gathers
information by medical record review, provider report at diagnosis, personal interviews with patients, and
HIV-related laboratory tests, which are electronically reported to surveillance for all cases receiving
diagnosis and/or care in NYC.
Individual-level data acquired from the registry included demographic and clinical information
collected at the time of first report, address of residence at diagnosis, and HIV-related laboratory test
results from 2006-2012 for all New Yorkers diagnosed with HIV. Laboratory reports contain the test type,
specimen collection date, result, and submitting provider or facility. Reports on existing cases are added
to their registry record; reports not matching an existing case are sent out for field investigation to confirm
11

the diagnosis and collect other required data. Health care facility data from 2006-2012 were obtained
from the registry and linked to cases according to the facility diagnosing each case with HIV. All registry
data used in this analysis were reported as of September 30, 2013. Finally, neighborhood data at the
Census tract level were acquired from the 2010 US Census and the 2011 American Community Survey
5-year estimates. Neighborhood data were linked to cases through the Census tract of patient residence,
which was geocoded from address of residence to the 2010 Census tract. The process of creating an
analytic dataset with individual, facility, and neighborhood data is described in Appendix 3.
Population
NYC residents who were newly diagnosed with HIV between 2006 and 2010 and at least 13
years of age at diagnosis (N=17,825 persons) were excluded if their address could not be geocoded to
Census tract (n=2,560), if their facility- or neighborhood-level characteristics were unknown (n=206), if
their address of residence and of facility of diagnosis were equivalent, possibly indicating a homeless or
institutionalized person (n=471), if they were diagnosed at a correctional facility (n=252), or if they did not
survive at least 31 days following diagnosis (n=220). We further excluded 1,569 persons with neither a
Western blot confirmatory test within 31 days of diagnosis nor a diagnosis of acute HIV infection (n=716);
persons with a detectable (>50 copies/mL) viral load >31 days prior to diagnosis (n=1); and persons with
a suppressed (≤400 copies/mL) viral load <31 days following diagnosis, values that indicate either elite
controllers or previous use of ART (n=852). These exclusions yielded an analytical sample of 12,547
persons (see Appendix 1).
Outcome
The outcome of interest was the first suppressed VL (≤400 copies of HIV RNA/mL plasma) after
HIV diagnosis. The cut-off was 400 copies/mL because this was the highest lower detectable limit of all
VL assays in use during the study period.[59] Persons were censored at death or the end of the follow-up
period, whichever came earlier. Follow-up time was calculated as the number of days from the date of
HIV diagnosis to suppression, death, or 12/31/2012, whichever came first.
Treatment guidelines evolved during the analysis period but recommended VL tests between 2-4
times per year after HIV diagnosis. However, some persons with HIV may have had infrequent or no VL
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tests after diagnosis, because they were never linked to HIV-related medical care, they sought care
infrequently, or their physician did not test their VL at every care visit. Persons who were not known to be
dead and who had no suppressed VL (including persons with infrequent or no VL tests) were presumed
not to be suppressed and contributed follow-up time as long as they were alive.
Covariates
Individual-level variables
Demographic characteristics (age, sex at birth, race/ethnicity, area of birth), HIV transmission risk
(also referred to as transmission categories), diagnosis date, viral loads, CD4 counts, and address of
residence at diagnosis were extracted from the NYC HIV surveillance registry. Age at HIV diagnosis was
calculated from birth date and date of diagnosis and categorized as 13-19, 20-29, 30-39, 40-49, 50-59,
and 60+.[2] Sex at birth was classified as male or female. Race was collected as white or Caucasian,
black or African American, Asian or Pacific Islander, and Native American. Ethnicity was collected as
Hispanic, non-Hispanic, or unknown. Race and ethnicity were combined into a single variable in which all
persons of Hispanic ethnicity were classified as Hispanic, and non-Hispanics were classified as black,
white, or other non-Hispanic race (which included Asians and Pacific Islanders, Native Americans, and
multiracial persons).[15] Area of birth was collected as country of birth when available or region of birth
and categorized as born in the US, US dependency (e.g., Puerto Rico), foreign country, or unknown place
of birth.[68] HIV transmission risk category was based on the self-reported pre-diagnosis risk behaviors
of the case (e.g., injection drug use, male-male sex) and the sex, HIV status (e.g., HIV-positive), and risk
(e.g., injection drug use) of the pre-diagnosis heterosexual-sex partners that s/he reports (which could
indicate high-risk heterosexual risk).[69] This information was combined into hierarchical, mutually
exclusive categories for the case: injection drug use (IDU), men who have sex with men (MSM),
heterosexual sex, and other or unknown (which included perinatal transmission).[15] To be classified as
a heterosexual male or female, persons must have reported pre-diagnosis sex with a partner of the other
sex who was HIV-infected, had injected drugs, or had received blood products. In addition, females only
could be classified as heterosexual if they had probable heterosexual transmission noted in their medical
record, reported sex with a male and no history of drug injection, or had any one of several behaviors
associated with heterosexual transmission: history of prostitution, multiple sex partners, sexually
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transmitted disease, crack/cocaine use, or sex with a bisexual male.[2] For analytic purposes, the year of
diagnosis was determined from the earlier of physician diagnosis date or positive Western blot test result
(2006, 2007, 2008, 2009, 2010). CD4 count (if any) at diagnosis (i.e., within 3 months of diagnosis) and
year of diagnosis vis-à-vis treatment guidelines were used to estimate treatment eligibility and as a proxy
for receipt of ART, on the presumption that the majority of persons reaching the federal treatment
threshold would be offered and receiving ART. Treatment-eligible persons included those diagnosed in
2006-2007 and with CD4<200, diagnosed in 2008-2009 and with CD4<350, or diagnosed in 2010 and
with CD4<500, reflecting changing treatment guidelines that increased the CD4 count at which ART
initiation was recommended.[70-72] All other persons, including those with no reported CD4 counts, were
not known to be eligible and were classified as not eligible.
Health care facility-level variables
Facility-level characteristics include annual HIV patient volume, facility type, and patient-facility
distance. HIV patient volume was collected as number of new HIV diagnoses made annually, based on
diagnoses attributed by surveillance to that facility in the year of the patient’s diagnosis, and categorized
as <10, 10-24, 25-49, 50-74, and ≥75 diagnoses per year.[33, 73] Facility type was categorized as
inpatient/hospital, private provider, other outpatient facility, screening/diagnosis/referral facility, and other
or unknown (<10 persons had a known facility but unknown type), as potential indicators of the availability
of colocated care (at the first three facility types) [35] and ancillary services (at the first and third types)
[32]. Patient-facility distance was calculated as the distance in miles along NYC streets from patient
residence to the facility of diagnosis (based on the XY coordinates of each) using Network Analyst in
ArcMap 10.0 (ESRI, Redmonds, CA) (see Appendix 4). This distance was categorized as <1 mile, 1-<5
miles, 5-<10 miles, and ≥10 miles.
Neighborhood-level variables
Analyses included two Census tract-level SES measures from 2011 American Community Survey
(ACS) 5-year estimates, which is the recommended source for such statistics because the 2010
decennial census did not collect them.[74] These measures, which previously have been associated with
HIV or sexually transmitted infections or HIV outcomes, were percent of residents with incomes under
federal poverty threshold,[31, 33, 39, 40, 47, 75] and percent unemployed among residents 16+,[31, 39,
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41, 75] Census 2010 provided data on percent of non-Hispanic black residents, as it is the recommended
data source for population race/ethnicity statistics. [74] The values for percent unemployed and percent
black were divided by 10 and entered into a proportional hazards regression as continuous variables;
measures of association would therefore be for 10-percentage-point differences. Poverty was
categorized as 0 to <10% (low-poverty), 10 to <20% (medium-poverty), 20 to <30% (high-poverty), and
30 to 100% (very-high-poverty), based on recommendations of the NYC health department.[76] This
particular set of three neighborhood-level variables (poverty, unemployment, and percent black) has been
used previously.[43]
Statistical analysis
Descriptive statistics were calculated for selected characteristics at the individual, health care
facility, and neighborhood levels and presented for the overall population and according to suppression
status within 12 months (365 days) of diagnosis. The association between each variable and
achievement of suppression within 12 months was measured using Chi-square tests. The Mann-Whitney
U test was used to ascertain differences in median days to suppression by the end of the follow-up
period.
Kaplan-Meier curves showing the number of days from diagnosis to suppression were generated
by key individual and health care facility characteristics, and log-rank tests were used to indicate
differences between groups.
We used Cox proportional hazards regressions to estimate the association of individual, facility,
and neighborhood-level factors with suppression in crude and adjusted models. Robust sandwich
estimation of the standard errors was used to account for correlations of individual outcomes clustered
within either facility of diagnosis or neighborhood (Census tract).[62, 63] Unadjusted models were fitted
to estimate the unadjusted hazards of viral suppression for each individual, facility, and neighborhood
characteristic. In addition, several models were fitted. First, hazards of viral suppression for each
individual characteristic were estimated after adjustment for all other individual characteristics. Second,
models were fitted to estimate the hazards for each facility and each neighborhood characteristic, after
controlling for individual characteristics. Finally, two models were fitted to estimate the adjusted hazards
for 1) all individual and facility characteristics and 2) all individual and neighborhood characteristics.
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All analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC). Ethical approval for these
analyses was provided by the Institutional Review Boards of Lehman College of the City University of
New York and of the NYC Department of Health and Mental Hygiene.

Results
Descriptive statistics
Of 12,547 New Yorkers newly diagnosed with HIV in 2006–2010, approximately three-quarters
were 20-49 years old (78.7%), male (74.2%), and black or Hispanic (81.5%; Table 2.1). In addition,
approximately half were US-born (53.5%) and MSM (44.5%), and about one-third were eligible to receive
treatment based on CD4 and diagnosis year (30.6%). Forty-four percent of the population achieved
suppression within 12 months of diagnosis. Those who did not suppress within 12 months were more
likely to be younger, black, US-born, MSM or IDU, diagnosed in earlier years, and not eligible for
treatment.
Almost three-quarters of the population (72.8%) achieved viral suppression by 12/31/2012 (not
shown), in a median of 245 days (Table 2.1). Suppression happened least quickly among persons who
were younger, diagnosed in earlier years, and not known to be eligible for treatment; differences were
most prominent by treatment eligibility (127 days among eligible vs. 415 days among not eligible),
differences also demonstrated in Kaplan-Meier survival curves (p<0.0001; Figure 2.1a).
Approximately half of the population was diagnosed in facilities that diagnosed 10-74 persons
(45.0%), were hospitals (42.7%), and were 1 to <5 miles from their home (51.0%; Table 2.2); and lived in
neighborhoods where ≥20% of the population was below the poverty threshold (i.e., high or very high
poverty; 58.0%). Neighborhoods where people lived had a mean unemployment rate of 10.8%, and black
persons comprised a mean of 34.3% of the population.
When compared to persons achieving suppression within 12 months of diagnosis, those who did
not achieve it were more likely to be diagnosed at facilities that diagnosed fewer persons with HIV, were
screening or outpatient facilities, and were ≥10 miles from the patient’s residence (Table 2.2); differences
in suppression by the first two characteristics were also visible in Kaplan-Meier survival curves (Figures
2.1b and 2.1c). Suppression happened least quickly among persons diagnosed at non-hospital facilities
and facilities farther from the patient’s residence.
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Modelling individual characteristics
Table 2.3 presents the unadjusted and adjusted HRs for individual characteristics on HIV viral
suppression among persons newly diagnosed with HIV in NYC. The unadjusted HRs show that persons
who were younger, male, black, US-born or MSM were at least 7% less likely to achieve viral suppression
(range 7% to 43%). The same decrement applied to those diagnosed before 2010 and those who were
not treatment-eligible.
After adjusting for individual characteristics, the likelihood of viral suppression was 16-29% lower
for persons 13-49 years old relative to those 60 and older (e.g., 20-29 years old, 24%[95%CI=0.67-0.86])
and 10% (95%CI=0.83-0.97) lower among men than women. Blacks and Hispanics were 19%
(95%CI=0.76-0.86) and 12% (95%CI=0.82-0.94) less likely to suppress than their white counterparts.
US-born persons were 8% (95%CI=0.87-0.97) less likely to suppression than foreign-born, and persons
diagnosed in 2006 and 2008 were at least 11% (e.g., 2006, 11%[95%CI=0.83-0.96]) less likely to
suppress than persons diagnosed in 2010. Compared with heterosexuals, MSM went from being less
likely (in crude models) to as or more likely (in models adjusting for other individual characteristics) to
suppress (AHR[95%CI]=1.08[1.00-1.17]). Finally, persons not eligible for treatment were 65% less likely
than treatment-eligible persons to suppress, presumably because treatment-eligible persons were more
likely to have been prescribed ART, almost the exclusive means of lowering viral load. These findings
remained nearly identical when adjusting for either facility or neighborhood characteristics (AHRs 2 and 3
in Table 2.3).
Modelling facility and neighborhood characteristics
Table 2.4 presents the unadjusted and adjusted HRs for facility and neighborhood characteristics
on HIV viral suppression among persons newly diagnosed with HIV in NYC. The unadjusted HRs show
that persons diagnosed at facilities diagnosing <10 patients per year or that were a type other than a
hospital were at least 10% less likely to achieve viral suppression (range 10% to 38%; e.g., outpatient
facilities, 25% [95%CI=0.71-0.79]). At facilities 1 to <5 miles from the patient vs. <1 mile, 8% more likely
(95%CI=1.02-1.14). Although marginally significant, each 10% increase in the proportion of
neighborhood residents that was unemployed or black was associated with, respectively, a 5%
(95%CI=0.92-0.99) and 1% (95%CI=0.98-0.99) lower likelihood of suppression.
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After adjusting for individual characteristics alone, and then individual characteristics as well as
either facility or neighborhood characteristics, facility-related findings remained similar as in the bivariate
models, with the exception of persons diagnosed at private physicians becoming more likely to achieve
suppression (when controlling for both individual and facility characteristics, AHR[95%CI]=1.08[0.951.22]). The model with all individual- and facility-level variables had the best fit (-2LL: 158,585; p<0.0001
vs. the model with all individual-level variables only; see Appendix 5). Neighborhood characteristics were
no longer associated with suppression in models adjusted for individual characteristics.

Discussion
Controlling for individual and facility characteristics, persons who were younger, male, non-white,
US-born, non-MSM, diagnosed in earlier years, and not eligible for treatment took longer to achieve HIV
viral suppression after diagnosis. Persons diagnosed at facilities that diagnosed relatively few patients or
that were screening, diagnosis, and referral sites also took longer to suppress. Neighborhood-level
characteristics did not influence the time from diagnosis to viral suppression.
Our findings about individual and facility characteristics were consistent with the literature.
Individual-level factors associated with suppression were similar to a previous study using NYC HIV
surveillance data.[15] After adjustment for other individual characteristics, MSM went from having slower
suppression than heterosexuals to as quickly or quicker. One possible explanation is that newly
diagnosed MSM were younger, healthier, and less likely to be eligible for ART than heterosexuals, but
compared with heterosexuals, MSM had equivalent or better treatment access generally and/or
adherence once on ART. However, our findings provided unique information about teenagers, who have
been included in few prior analyses of viral suppression. Our analysis found teenagers to have, relative
to persons ≥60 years old, similarly reduced rates of suppression as persons in their 20s. Teenagers are
known to face challenges linking to care after diagnosis, being retained in care, and adhering to ART to
achieve suppression;[77, 78] these age-related disparities are not entirely attributable to teenagers being
in an earlier stage of disease than older persons. Persons diagnosed at facilities that diagnosed fewer
patients or that only screened, diagnosed, and referred patients had lower rates of suppression than
persons diagnosed elsewhere. It is possible that these facilities were less likely to provide on-site HIVrelated medical care or services for retention, adherence, and case management, which have been
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shown to facilitate linkage after diagnosis[35] and retention in care;[79, 80] or because their providers are
less likely to adhere to HIV-related care recommendations.[81]
Findings about neighborhood characteristics were not consistent with the scant literature on their
relationship with HIV outcomes. While neighborhood-level socioeconomic factors have been associated
with HIV diagnosis rates in NYC and elsewhere, and some care-related outcomes,[31, 33, 38-42] in our
analysis, neighborhood characteristics were not associated with time to suppression once diagnosed.
Several possible explanations include different outcomes (e.g., time from ART initiation to suppression vs.
time from diagnosis to suppression) and different settings (e.g., Canada vs. US, or other US areas vs.
NYC). Accessible, effective HIV care is perhaps available regardless of characteristics of the NYC
neighborhood in which people live, mitigating neighborhood-level disadvantage after diagnosis. Finally,
publication bias may have limited the publication of previous null findings on neighborhood characteristics
and HIV outcomes.[82, 83]
Being diagnosed at a facility 1 to <5 miles from one’s residence was also associated with quicker
suppression relative to ≥10 miles away, suggesting that proximity may be important, although interestingly
persons diagnosed at facilities within one mile of their residences did not share this advantage. These
were not known to be institutionalized persons, who were excluded from the analysis because their
outcomes might be influenced by neighborhood and facility differently than non-institutionalized persons.
Rather, perhaps facilities <1 mile from persons’ residences were disproportionately (a) offices of their
regular (i.e., pre-HIV-infection) primary care physicians and/or (b) selected for convenience. In either
case, staff may have had less expertise in managing HIV or making effective linkages to HIV specialty
care. This hypothesis is feasible if these factors are independent from patient volume and facility type,
which were controlled for. Unfortunately, we did not know the mode of transportation nor time required to
get to the facility, which may at least partially explain why persons <1 mile from their facilities did not
experience quickest suppression. An analysis on correlates of the distance that persons with HIV in
another Northeast US city, Philadelphia, travel for care found that greater patient distance from the
nearest care site was associated with non-achievement of viral suppression, among persons who had
been retained.[84] However, distance was not associated with progression along other parts of the
continuum of HIV-related medical care, from diagnosis to retention.[10, 13, 84] That difference in the
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analyses (where ours followed persons from diagnosis to suppression and theirs from retention to
suppression) may account for the different findings.
Limitations
As in any population-based analysis of HIV care, ours had VL data only when persons sought
care, which was at their discretion. Persons in this analysis were not necessarily tested at regular
intervals and may have achieved suppression sometime before it was measured in a VL test. It is not
clear whether these circumstances would have over- or underestimated our hazard ratios. However,
most persons in the analysis (88%) had at least one VL test between 8 days post-diagnosis and death
(Appendix 6). Among that 88%, persons diagnosed in 2006, with the most follow-up, had a median of 17
VL tests (IQR: 10-23) and the median interval between tests was 120 days (4 months; IQR: 95-182 days),
while persons diagnosed in 2010 had a median of 8 tests (IQR: 5-10) and the median interval between
tests was 101 days (3 months; IQR: 85-139 days). These estimates indicate that the majority of New
Yorkers newly diagnosed with HIV between 2006 and 2010 were engaged in care at intervals that were
both consistent with federal guidelines and sufficiently frequent to produce population-level estimates of
suppression.
Persons not in care in NYC were presumed to be present and unsuppressed, although they may
have moved out of NYC and become suppressed elsewhere. Non-ascertainment of outmigration is a
typical limitation of local HIV surveillance data. An analysis of mobility among NYC AIDS cases who died
found that males, whites, MSM, and younger persons were more likely to have left the city;[85] it is
possible that the same demographic and risk groups are more likely to leave NYC shortly after HIV
diagnosis and thus have undetected suppression. All of these circumstances increase the apparent time
to suppression overall, and higher outmigration in some groups could result in differential
underascertainment of suppression. This may have overestimated the male-female disparity in
suppression rates (i.e., made the HR for males lower) but underestimated disparities by race/ethnicity and
risk (i.e., decreased the HRs for white and MSM), since whites and MSM were most likely, in multivariable
models, to achieve suppression.
We note that a newly diagnosed person who is in NYC but not in care and not getting blood
drawn for viral load tests cannot receive ART by prescription and therefore is unlikely to be suppressed;
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as such, there is likely little underascertainment of suppression among persons actually in NYC.
Additionally, newly diagnosed persons were known to be in NYC as recently as their diagnoses, if not at
later points of care, and thus have had relatively little time to leave NYC. Further, the system of care and
services, comparatively generous benefits, and large HIV-positive population in NYC make it a relatively
attractive place for HIV-positive persons to live and receive care.
There are several steps between diagnosis and suppression in the continuum of care for HIVpositive persons.[10, 13] By design, this analysis did not elucidate the exact step(s) at which facility-level
factors affect suppression. Other analyses have investigated the role of facility or health care services in
intermediate steps in the continuum, such as time from diagnosis to linkage,[35, 86] continuous care or
retention in care,[79, 80, 87] and ART use and suppression among persons in care.[88]
Characteristics measured at one level may have acted at another level. For example, poverty
was measured at the neighborhood level only and was found not to be significantly associated with
suppression. It is possible that there is no association between individual-level poverty, which we could
not measure, and suppression, or alternatively, that individual-level poverty would in fact have been
associated with suppression. This limitation is not unique to our analysis but rather is a characteristic
shortcoming of multilevel analyses.[89, 90]
Strengths
This is among the first analyses in the US to investigate the influence of facility and neighborhood
on HIV outcomes using surveillance data. [31, 33, 35, 87] The data were drawn from population
surveillance in the largest HIV epidemic in the US, in a diverse US city. It combined data from multiple
sources to assess the potential influence on viral suppression of factors beyond the individual.
Mandatory electronic reporting of laboratory tests in NYC provided information about all measured VLs for
all HIV-positive persons receiving care in NYC, as opposed to in a clinical trials environment, where
findings can differ from those in a population setting. We filled a gap in the literature by including
teenagers, who are subject to the same treatment guidelines as adults but whose young age may have
contributed to slower suppression than among older persons.[78] To assign area-based characteristics to
individuals, we used patient address geocoded to the Census tract, which is the gold standard for

21

detection of public health disparities;[47] other geographic analyses of HIV care outcomes have used only
counties and ZIP codes, which are much larger than Census tracts.
Conclusions
We have identified individual and facility characteristics that seem to help persons newly
diagnosed with HIV to achieve viral suppression, thus improving their health and preventing ongoing HIV
transmission. Those persons or health care facilities with characteristics associated with slower
achievement of suppression may need more assistance after diagnosis with linkage to and retention in
care or ART prescribing and adherence. For example, black persons may benefit from more-frequent
medical care and prescription of ART that permits them to become suppressed at comparable rates as
whites;[15, 22, 25-27, 91] rectifying this disparity may require more equitable prescribing behavior and/or
better adherence support.[92] NYC can continue to encourage HIV testing at large facilities, including
hospitals, where patients have the greatest likelihood of reaching suppression quickly. We can also
increase the capacity of facilities that make fewer diagnoses annually, or that are neither hospitals nor
private physicians’ offices, to move their patients along the continuum of care from diagnosis to
suppression, even if this means ensuring effective linkage to care at another site that has cared for more
HIV-positive patients. Since 2010, New York State law has required all providers to link positive patients
to care, and the United States Department of Health and Human Services now encourages antiretroviral
therapy for all diagnosed persons, regardless of CD4 count, which should further the improvement in
suppression rates. Future studies should monitor whether facility-level disparities in suppression
decrease over time, as more facilities presumably adhere to the law.
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Table 2.1. Achievement of HIV viral suppression among persons newly diagnosed with HIV in New York City in 2006-2010
and followed through 2012, by individual-level characteristics
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Total
Age group (years) at diagnosis
13 – 19
20 – 29
30 – 39
40 – 49
50 – 59
≥60
Sex at birth
Male
Female
Race/Ethnicity
Black
Hispanic
White
Other
Country of birth
US
US Dependency
Foreign

Total

Not
virologically
suppressed
within 12
months

Distribution (n)
100.0 (12,547)

Distribution (n)
100.0 (7,031)

4.7 (590)
27.9 (3,497)
26.2 (3,290)
24.6 (3,087)
12.0 (1,502)
4.6 (581)

5.8 (405)
30.9 (2,172)
26.6 (1,868)
23.1 (1,627)
10.0 (701)
3.7 (258)

Virologically suppressed within 12
months

Distribution (n) Prevalence
100.0 (5,516)
44.0

p-value1
<0.0001

3.4 (185)
24.0 (1,325)
25.8 (1,422)
26.5 (1,460)
14.5 (801)
5.9 (323)

31.4
37.9
43.2
47.3
53.3
55.6
0.0009

74.2 (9,309)
25.8 (3,238)

75.3 (5,297)
24.7 (1,734)

72.7 (4,012)
27.3 (1,504)

43.1
46.4
0.0009

49.1 (6,162)
32.3 (4,058)
15.2 (1,912)
3.3 (415)

50.5 (3,552)
31.6 (2,223)
14.9 (1,049)
2.9 (207)

47.3 (2,610)
33.3 (1,835)
15.6 (863)
3.8 (208)

42.4
45.2
45.1
50.1
<0.0001

53.5 (6,713)
4.5 (565)
31.5 (3,951)

56.9 (4,002)
4.4 (312)
27.7 (1,947)

49.1 (2,711)
4.6 (253)
36.3 (2,004)

40.4
44.8
50.7

Median time from
diagnosis to
suppression
Median
(IQR2)
days p-value3
245 (532)
<0.0001
436 (772)
339 (633)
255 (551)
210 (453)
178 (334)
150 (228)
<0.0001
263 (550)
206 (463)
0.0003
236 (533)
248 (515)
285 (568)
186 (367)
<0.0001
291 (592)
234 (475)
194 (401)
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Unknown
HIV transmission risk
Men who have sex with men
Injection drug use history
Heterosexual
Other or unknown
Year of HIV diagnosis
2006
2007
2008
2009
2010
Eligible for treatment
Yes
No

10.5 (1,318)

11.0 (770)

9.9 (548)

41.6

263 (566)
<0.0001

44.5 (5,580)
5.2 (653)
25.5 (3,198)
24.8 (3,116)

46.0 (3,236)
5.4 (380)
23.8 (1,672)
24.8 (1,743)

42.5 (2,344)
4.9 (273)
27.7 (1,526)
24.9 (1,373)

42.0
41.8
47.7
44.1

<0.0001
304 (606)
273 (524)
206 (461)
202 (440)

<0.0001
20.5 (2,570)
20.5 (2,569)
21.0 (2,641)
19.8 (2,486)
18.2 (2,281)

22.6 (1,587)
22.2 (1,559)
21.3 (1,496)
18.8 (1,320)
15.2 (1,069)

17.8 (983)
18.3 (1,010)
20.8 (1,145)
21.1 (1,166)
22.0 (1,212)

38.2
39.3
43.4
46.9
53.1

<0.0001
363 (935)
326 (661)
245 (550)
211 (380)
170 (255)

<0.0001
30.6 (3,834)
69.4 (8,713)

14.5 (1,016)
85.5 (6,015)

51.1 (2,818)
48.9 (2,698)

1

p-value: Chi-square test of association between each variable and achievement of suppression

2

IQR: Interquartile range, i.e., 3rd quartile minus 1st quartile

3

p-value: Mann-Whitney U test of differences by each variable in median days to suppression

73.5
31.0

<0.0001
127 (141)
415 (708)

Table 2.2. Achievement of HIV viral suppression among persons newly diagnosed with HIV in New York City in 2006-2010
and followed through 2012, by characteristics of the health care facility at which persons were diagnosed and the
neighborhood (Census tract) persons were living in at diagnosis

Total
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Total
Facility-level variables
Number of HIV diagnoses made
annually by health care facility
that diagnosed patient
<10
10 to 24
25 to 49
50 to 74
≥75
Type of facility that diagnosed
patient
Hospital
Outpatient
Private physician
Screening/diagnosis/referral
Other or unknown
Distance between patient and
facility

Distribution
(n) or Mean
(SD)
100.0 (12,547)

Not
virologically
suppressed
within 12
months

Distribution (n)
100.0 (7,031)

Virologically suppressed within 12
months

Distribution (n) Prevalence
100.0 (5,516)
44.0

p-value1

Median time from
diagnosis to
suppression
Median
(IQR2)
days
245 (532)

0.0007
33.2 (4,169)
13.9 (1,741)
16.5 (2,073)
14.6 (1,828)
21.8 (2,736)

34.1 (2,396)
13.9 (974)
17.2 (1,208)
14.3 (1,004)
20.6 (1,449)

32.1 (1,773)
13.9 (767)
15.7 (865)
14.9 (824)
23.3 (1,287)

42.5
44.1
41.7
45.1
47.0

0.1165
256 (566)
235 (454)
265 (582)
219 (486)
245 (507)

<0.0001
42.7 (5,358)
22.8 (2,865)
18.6 (2,332)
13.9 (1,743)
2.0 (249)

37.9 (2,668)
25.2 (1,769)
18.2 (1,283)
16.3 (1,148)
2.3 (163)

48.8 (2,690)
19.9 (1,096)
19.0 (1,049)
10.8 (595)
1.6 (86)

pvalue3

50.2
38.3
45.0
34.1
34.5

<0.0001
195 (405)
315 (606)
261 (567)
350 (636)
253 (573)

<0.0001

0.0002
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<1 mile
1 to <5 miles
5 to <10 miles
≥10 miles
Neighborhood-level variables
Percent of population below
federal poverty threshold in past
12 months
Low (<10%)
Medium (10 to <20%)
High (20 to <30%)
Very high (≥30%)
Unemployment rate among
population 16 years and over
Percent of population that is
black or African American only
(non-Hispanic)
1

21.4 (2,683)
51.0 (6,398)
20.0 (2,509)
7.6 (957)

22.3 (1,569)
49.1 (3,452)
20.3 (1,428)
8.3 (582)

20.2 (1,114)
53.4 (2,946)
19.6 (1,081)
6.8 (375)

41.5
46.0
43.1
39.2

266 (579)
225 (495)
273 (524)
280 (568)

0.0304

0.1715

15.9 (1,992)
26.1 (3,280)
25.1 (3,153)
32.9 (4,122)

15.4 (1,081)
25.9 (1,821)
24.8 (1,745)
33.9 (2,384)

16.5 (911)
26.5 (1,459)
25.5 (1,408)
31.5 (1,738)

45.7
44.5
44.7
42.2

10.8 (5.6)

-

-

-

N/A

-

N/A

34.3 (29.2)

-

-

-

N/A

-

N/A

p-value: Chi-square test of association between each variable and achievement of suppression

2

IQR: Interquartile range, i.e., 3rd quartile minus 1st quartile

3

p-value: Mann-Whitney U test of differences by each variable in median days to suppression

228 (482)
245 (517)
234 (515)
267 (571)

Table 2.3. Proportional hazards regressions of HIV viral suppression among persons newly diagnosed with HIV in New
York City in 2006-2010 and followed through 2012, by individual-level characteristics
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Age group (years) at diagnosis
13 - 19
20 - 29
30 - 39
40 - 49
50 - 59
≥60
Sex at birth
Male
Female
Race/Ethnicity
Black
Hispanic
White
Other
Country of birth
US
US Dependency
Foreign
Unknown
HIV transmission risk
Men who have sex with men
Injection drug use history
Heterosexual

HR
(95% CI)1

AHR 1
(95% CI)1,2

AHR 2
(95% CI)1,3

AHR 3
(95% CI)1,4

0.57 (0.49-0.65)
0.64 (0.57-0.72)
0.69 (0.61-0.77)
0.76 (0.67-0.85)
0.88 (0.78-1.00)
1.00

0.71 (0.61-0.83)
0.76 (0.67-0.86)
0.78 (0.69-0.88)
0.84 (0.74-0.94)
0.94 (0.83-1.06)
1.00

0.75 (0.64-0.86)
0.79 (0.69-0.90)
0.80 (0.71-0.90)
0.85 (0.76-0.95)
0.95 (0.84-1.08)
1.00

0.71 (0.61-0.83)
0.76 (0.67-0.86)
0.78 (0.69-0.88)
0.84 (0.74-0.94)
0.94 (0.83-1.06)
1.00

0.93 (0.89-0.97)
1.00

0.90 (0.83-0.97)
1.00

0.90 (0.83-0.97)
1.00

0.89 (0.83-0.97)
1.00

0.83 (0.78-0.88)
0.94 (0.88-1.00)
1.00
1.03 (0.90-1.18)

0.81 (0.76-0.86)
0.88 (0.82-0.94)
1.00
0.89 (0.77-1.03)

0.84 (0.79-0.90)
0.91 (0.85-0.98)
1.00
0.91 (0.79-1.05)

0.81 (0.75-0.87)
0.87 (0.81-0.94)
1.00
0.89 (0.77-1.03)

0.84 (0.81-0.88)
0.95 (0.86-1.06)
1.00
0.80 (0.74-0.86)

0.92 (0.87-0.97)
0.98 (0.88-1.10)
1.00
0.88 (0.81-0.95)

0.92 (0.87-0.98)
0.99 (0.88-1.10)
1.00
0.87 (0.79-0.95)

0.92 (0.87-0.97)
0.98 (0.88-1.10)
1.00
0.88 (0.81-0.95)

0.93 (0.88-0.97)
0.87 (0.79-0.96)
1.00

1.08 (1.00-1.17)
0.92 (0.82-1.02)
1.00

1.11 (1.02-1.19)
0.93 (0.84-1.04)
1.00

1.09 (1.00-1.18)
0.92 (0.82-1.02)
1.00

Other or unknown
Year of HIV diagnosis
2006
2007
2008
2009
2010
Eligible for treatment
Yes
No

0.83 (0.78-0.88)

0.86 (0.79-0.93)

0.86 (0.79-0.93)

0.86 (0.79-0.93)

0.67 (0.63-0.72)
0.71 (0.67-0.76)
0.74 (0.70-0.80)
0.84 (0.79-0.90)
1.00

0.89 (0.83-0.96)
0.94 (0.87-1.01)
0.87 (0.81-0.93)
1.02 (0.95-1.10)
1.00

0.87 (0.81-0.95)
0.92 (0.85-1.00)
0.86 (0.79-0.93)
1.02 (0.95-1.10)
1.00

0.89 (0.83-0.95)
0.94 (0.87-1.01)
0.87 (0.81-0.93)
1.02 (0.95-1.10)
1.00

1.00
0.34 (0.32-0.36)

1.00
0.35 (0.33-0.37)

1.00
0.36 (0.34-0.38)

1.00
0.35 (0.33-0.37)

1

Hazard ratios and confidence intervals for models with only individual- or neighborhood-level variables account for clustering by Census tract, and those
with facility-level variables account for clustering by facility of diagnosis. Hazard ratios (HR) are unadjusted unless indicated as “AHR.”
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2

Adjusted hazard ratio 1: For each individual-level variable, adjusting for all other individual-level variables

3

Adjusted hazard ratio 2: For all individual-level variables, adjusting for all facility-level variables

4

Adjusted hazard ratio 3: For all individual-level variables, adjusting for all neighborhood-level variables

Table 2.4. Proportional hazards regressions of HIV viral suppression among persons newly diagnosed with HIV in New
York City in 2006-2010 and followed through 2012, by characteristics of the health care facility at which persons were
diagnosed and the neighborhood (Census tract) persons were living in at diagnosis
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Facility-level variables
Number of HIV diagnoses made annually by
health care facility that diagnosed patient
<10
10 to 24
25 to 49
50 to 74
≥75
Type of facility that diagnosed patient
Hospital
Outpatient
Private physician
Screening/diagnosis/referral
Other or unknown
Distance between patient and facility
<1 mile
1 to <5 miles
5 to <10 miles
≥10 miles
Neighborhood-level variables5
Percent of population below federal poverty
threshold in past 12 months
Low (<10%)
Medium (10 to <20%)

HR
(95% CI)1

AHR 1
(95% CI)1,2

AHR 2
(95% CI)1,3

0.85 (0.80-0.90)
0.82 (0.77-0.88)
0.83 (0.78-0.89)
0.87 (0.81-0.93)
1.00

0.93 (0.85-1.01)
0.85 (0.76-0.95)
0.85 (0.77-0.93)
0.88 (0.81-0.95)
1.00

0.90 (0.81-1.01)
0.87 (0.79-0.95)
0.85 (0.78-0.92)
0.87 (0.80-0.94)
1.00

1.00
0.75 (0.71-0.79)
0.90 (0.85-0.95)
0.65 (0.61-0.70)
0.62 (0.53-0.73)

1.00
0.91 (0.86-0.96)
1.05 (0.99-1.11)
0.84 (0.78-0.90)
0.78 (0.66-0.92)

1.00
0.93 (0.84-1.02)
1.08 (0.95-1.22)
0.86 (0.80-0.92)
0.80 (0.62-1.02)

1.00
1.08 (1.02-1.14)
1.01 (0.95-1.08)
0.93 (0.85-1.01)

1.00
1.08 (1.03-1.14)
1.04 (0.98-1.11)
0.99 (0.90-1.08)

1.00
1.09 (1.03-1.15)
1.04 (0.96-1.12)
0.99 (0.90-1.10)

1.00
0.98 (0.92-1.04)

1.00
0.98 (0.92-1.06)

AHR 3
(95% CI)1,4

1.00
0.99 (0.92-1.06)

High (20 to <30%)
Very high (≥30%)
Unemployment rate among population 16
years and over
Percent of population that is black or African
American only (non-Hispanic)
1

1.00 (0.94-1.07)
0.95 (0.89-1.01)

1.03 (0.95-1.11)
1.01 (0.94-1.09)

1.03 (0.95-1.11)
1.01 (0.93-1.10)

0.95 (0.92-0.99)

1.00 (0.96-1.05)

1.00 (0.95-1.05)

0.99 (0.98-0.99)

1.00 (0.99-1.01)

1.00 (0.99-1.01)

Hazard ratios and confidence intervals for facility-level variables account for clustering by facility of diagnosis, and those for neighborhood-level variables
account for clustering by Census tract. Hazard ratios (HR) are unadjusted unless indicated as “AHR.”
2
Adjusted hazard ratio 1: For each facility- or neighborhood-level variable, adjusting for all individual-level variables
3
Adjusted hazard ratio 2: For all facility-level variables, adjusting for all individual-level variables
4
Adjusted hazard ratio 3: For all neighborhood-level variables, adjusting for all individual-level variables
5
Hazard ratios presented for continuous variables (percent unemployed and percent black) represent the risk per 10-percentage-point increase in the
variable.
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Figure 2.1. Kaplan-Meier survival curves of time from HIV diagnosis to viral suppression
among persons newly diagnosed with HIV in New York City in 2006-2010 and followed
through 2012

Figure 2.1a. By eligibility for antiretroviral therapy (ART) at diagnosis (p<0.01)
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Figure 2.1b. By patient volume (the number of HIV diagnoses made annually by the health care
facility that diagnosed the patient) (p<0.01)
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Figure 2.1c. By type of facility that diagnosed the patient (p<0.01)
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Chapter 3. Multilevel analysis of individual, health care facility, and neighborhood
characteristics associated with HIV virologic failure after suppression among
persons newly diagnosed with HIV in New York City
Introduction
New York City (NYC) is home to more than 7% of all persons newly diagnosed with HIV in the
United States (US) each year.[1, 2] Reduction of each person’s HIV viral load (VL) to low or undetectable
levels (e.g., ≤400 copies/mL) is called viral suppression and is typically achieved by antiretroviral therapy
(ART) treatment.[4] Viral suppression slows progression of HIV disease [7] and reduces the likelihood of
onward sexual transmission.[8] As few as 20% of PLWHA were thought to be suppressed in the US in
the early 2000s, while today most estimates exceed 50%;[10-14] in NYC, it was 59% in 2010.[14] The
US National HIV/AIDS Strategy’s 2015 goal is a 20% increase in the proportion of persons virally
suppressed, within several populations most affected by HIV (blacks, Hispanics, and gay and bisexual
men).[9]
Epidemiologic studies have rarely examined VL over time or in terms of factors other than
individual demographics and clinical characteristics. Most published population-level viral suppression
estimates, including those in the HIV care continuum literature, refer only to the most recent VL
measure.[10, 13] A single VL measure may not indicate maintenance of suppression (also referred to as
sustained suppression).[16] The few population-based studies following individuals’ viral loads over time
have found that a substantial proportion do not maintain suppression long; for example, 18% of New
Yorkers newly diagnosed in 2006-2009 experienced virologic failure (loss after achievement of
suppression) within 12 months of suppression.[15, 17-19] While the main driver of virologic failure is poor
adherence to ART, a study using NYC data found that more rapid failure after suppression was also
associated with individual-level demographic characteristics, e.g., black race, younger age, female sex at
birth, baseline clinical status indicators such as CD4 count and VL, and earlier calendar year of diagnosis
(i.e., failure rates have declined over time).[15] Further, some of these characteristics are known
mediators of adherence. Studies of virologic failure may benefit from the addition of variables describing
more macro-level or structural factors, such as the characteristics of the health care facilities where
people receive care and the neighborhoods where they live. For example, facility characteristics, such as
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type of clinical setting, accessibility (including travel distance for patients), the support offered to patients,
and physician experience have been shown to influence intermediary outcomes such as receipt of and
adherence to ART, both necessary steps for achievement and maintenance of suppression.[31-34]
Moreover, neighborhood factors such as lower area-level socioeconomic status have been associated
with delayed initiation of treatment and excess mortality.[31, 33, 39, 43, 93] However, few studies on
virologic failure have included facility or neighborhood characteristics.

Information about the characteristics associated with virologic failure is now included in many HIV
surveillance registries [15, 25, 52], and these characteristics will become increasingly important to identify
as more persons with HIV receive ART and achieve suppression. Thus, to examine these factors, we
investigated the effect of individual, health care facility, and neighborhood characteristics on HIV virologic
failure among New York City residents aged 13 years and older who were diagnosed with HIV between
2006 and 2010 and had achieved viral suppression. The results of this analysis may be used to improve
public health by identifying groups of persons who, because of individual or structural factors, are
vulnerable to virologic failure and who might benefit from interventions accounting for these factors to
improve ART adherence.

Methods
Data sources
This retrospective analysis used data from the NYC HIV surveillance registry reported by
September 30, 2013, the 2010 US Census,[54] and the 2011 American Community Survey.[55] The
surveillance registry includes all persons diagnosed and reported with AIDS in NYC since 1981 and HIV
since 2000. It gathers information by medical record review, provider report at diagnosis, personal
interviews with patients, and HIV-related laboratory tests, which are electronically reported to surveillance
for all cases diagnosed and/or receiving care in NYC.
The surveillance registry includes individual-level demographic and clinical information collected
at the time of first report of HIV diagnosis or first VL test indicating suppression, address of residence at
diagnosis, and HIV-related laboratory test results from 2006-2012 for all New Yorkers newly diagnosed
with HIV and achieving viral suppression. Laboratory reports contain the test type, specimen collection
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date, result, and submitting provider or facility. Health care facility data from 2006-2012 were obtained
from the registry and linked to cases according to the facility that conducted the first VL test indicating
suppression for each case. Finally, neighborhood data were acquired from the 2010 US Census and the
2011 American Community Survey 5-year estimates. Patient address of residence at diagnosis, obtained
from the registry, was geocoded to the Census tract to link tract-level neighborhood data from the US
Census and American Community Survey to individuals. Although the baseline time point for this analysis
was first viral suppression, residence at diagnosis rather than at first suppression was used because
Census tract-level residence data at first suppression were not available.
Population
Our analysis population was drawn from NYC residents who were newly diagnosed with HIV
between 2006 and 2010, were at least 13 years of age at diagnosis, and achieved viral suppression
(≤400 copies/mL) ≥31 days following diagnosis and by 12/31/2012 (N=10,232 persons). The cut-off for
suppression was 400 copies/mL because this was the highest lower detectable limit of all VL assays
being used during the study period.[59] Persons were then excluded from the analysis population if their
death date appeared to precede their first suppression date (n=6), they had an HIV diagnosis date that
was potentially misclassified (n=653; e.g., they had neither a Western blot confirmatory test within 31
days of diagnosis nor a diagnosis of acute HIV infection), the name of the facility of diagnosis or
suppression was missing (n=15), their address of residence and of facility of diagnosis or suppression
were equivalent, possibly indicating a homeless or institutionalized person, for whom characteristics of
the neighborhood of residence might influence health outcomes differently (n=415), they were diagnosed
or suppressed at a correctional facility or suppressed at a screening/diagnostic facility, possibly indicating
an institutionalized person or a misclassified care facility type (n=205), or their neighborhood-level
characteristics were unknown (n=11). These exclusions yielded an analytical sample of 8,927 persons
(see Appendix 1).
Outcome
The outcome of interest was virologic failure, defined as having a VL ≥1,000 copies/mL or not
having any VL test for 12 consecutive months. The 1,000-copy cutoff permitted a modest increase in VL
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above 400 that would not necessarily signal virologic failure but rather perhaps just a “blip.”[60]
Additionally, risk of HIV transmission from a person with VL up to 1000 is low.[8, 61] Requiring VL tests
every 12 months in order to be classified as maintaining suppression ensured at least minimal
engagement in care, as quarterly testing is recommended for most persons with HIV.[70] The 12-month
requirement also provided an endpoint for persons who dropped out of care, since care is required to
detect any VL, and it was not reasonable to assume that persons who dropped out of care in NYC would
remain suppressed. Censoring occurred at whichever came earlier: death or the end of the follow-up
period. Follow-up time was calculated as the number of days from the date of first viral suppression after
HIV diagnosis to the earliest of these dates: virologic failure, death, or 12/31/2012.
Covariates
Individual-level variables
Most of the demographic characteristics in our analyses were shown in previous analyses to be
associated with virologic failure among newly diagnosed New Yorkers who had achieved viral
suppression.[15] Demographic characteristics (age, sex at birth, race/ethnicity, area of birth), HIV
transmission risk (also referred to as transmission categories), viral suppression date, viral loads, CD4
counts, and address of residence at diagnosis were acquired from the NYC HIV surveillance registry.
Age at viral suppression was calculated from birth date to date of first suppression and
categorized as 13-19, 20-29, 30-39, 40-49, 50-59, and 60+.[2] Sex at birth was specified as collected,
male or female. Race was collected as white or Caucasian, black or African American, Asian or Pacific
Islander, and Native American. Ethnicity was collected as Hispanic, non-Hispanic, or unknown. Race
and ethnicity were combined into a single variable in which all persons of Hispanic ethnicity were
classified as Hispanic, and non-Hispanics were classified as black, white, or other non-Hispanic race
(which included Asians and Pacific Islanders, Native Americans, and multiracial persons).[15] Area of
birth was collected as country of birth when available or region of birth and categorized as born in the US,
US dependency (e.g., Puerto Rico), foreign country, or unknown place of birth.[68]
HIV transmission risk category was based on pre-diagnosis risk behaviors documented in the
medical record and/or self-reported at the time of diagnosis (e.g., injection drug use, male-male sex) and
the sex, HIV status (e.g., HIV-positive), and risk (e.g., injection drug use) of the pre-diagnosis
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heterosexual-sex partners reported by the case.[69] This information was combined into hierarchical
categories: injection drug use, men who have sex with men, heterosexual sex, and other or unknown
(which included perinatal transmission).[15] To be classified as most likely having acquired HIV through
heterosexual sex, persons must have reported pre-diagnosis sex with a partner of the other sex who was
HIV-infected, had injected drugs, or had received blood products. In addition, females could be classified
as heterosexual if they had probable heterosexual transmission noted in their medical record, reported
sex with a male and no history of drug injection, or had any one of several behaviors associated with
heterosexual transmission (history of prostitution, multiple sex partners, sexually transmitted disease,
crack/cocaine use, or sex with a bisexual male).[2]
CD4 count (if any) at suppression was based on the first CD4 count within 31 days before or after
suppression and categorized as 0-199, 200-349, 350-499, and ≥500 cells/mL.
Health care facility-level variables
Characteristics of the facility of first suppression include annual HIV patient volume, type, and
patient-to-provider distance, all of which could be ascertained or calculated based on information in the
NYC HIV surveillance registry. HIV patient volume was collected as number of HIV-positive patients cared
for annually, based on persons receiving a VL or CD4 test (as reported to surveillance) at that facility in
the year of the patient’s viral suppression, and categorized as <250, 250-999, 1,000-1,999, and ≥2,000
patients per year.[33, 73] Facility type was categorized as hospital, private physician (also referred to as
private practice), other outpatient facility, and other or unknown (<10 persons had a known facility but
unknown type), as potential indicators of the availability of ancillary services (at the first and third types)
[32]. These two variables of HIV patient volume and facility type were further combined (see Appendix 7),
with patient volume dichotomized as <1,000 (small) and ≥1,000 (large), to better capture underlying
concepts. Patient-provider distance was calculated as the distance in miles using the most direct street
route from patient residence to the facility where suppression was first detected (based on the XY
coordinates of each) using Network Analyst in ArcMap 10.0 (ESRI, Redmonds, CA) and a network
dataset of NYC streets that is used within the NYC Department of Health and Mental Hygiene (see
Appendix 4). This distance was categorized as <1 mile, 1-<5 miles, 5-<10 miles, and ≥10 miles.
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Neighborhood-level variables
Analyses included two Census tract-level SES measures from 2011 American Community Survey
(ACS) 5-year estimates; this is the recommended source for such statistics because the 2010 decennial
census did not collect them.[74] These measures have previously been associated with HIV or sexually
transmitted infections or HIV outcomes and include percent of residents with incomes under the federal
poverty threshold[31, 33, 39, 40, 47, 75] and percent unemployed among residents aged 16 years and
older.[31, 39, 41, 75] Census 2010 provided data on percent of non-Hispanic black residents.[74] The
values for percent unemployed and percent black were divided by 10 and entered into a proportional
hazards regression as continuous variables with every unit representing a 10-percentage-point difference.
Poverty was categorized as 0 to <10% (low-poverty), 10 to <20% (medium-poverty), 20 to <30% (highpoverty), and 30 to 100% (very-high-poverty), based on recommendations of the NYC health
department.[76] These particular neighborhood-level variables (poverty, unemployment, and black race)
have been used together previously.[43]
Statistical analysis
Descriptive statistics were calculated for selected characteristics at the individual, facility, and
neighborhood levels and presented for the overall population and according to virologic failure status
within 12 months (365 days) of suppression. Association between each variable and virologic failure
within 12 months was measured using Chi-squared tests. Differences in median days to failure by the
end of the follow-up period were determined using Mann-Whitney U test.
Kaplan-Meier curves showing the number of days from suppression to failure were generated by
key individual, health care facility, and neighborhood characteristics. Log-rank tests were used to indicate
differences between groups.
Cox proportional hazards regressions estimated the association of individual, facility, and
neighborhood-level factors with failure in crude and adjusted models. Robust sandwich estimation of the
standard errors was used to account for correlations of individual outcomes within either facility of
suppression or neighborhood (Census tract).[62, 63] We fit several models after estimating unadjusted
rates for virologic failure for each individual, facility, and neighborhood characteristic. We began by
estimated hazards of virologic failure for each individual characteristic after adjustment for all other
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individual characteristics (i.e., without any facility or neighborhood characteristics). Next, we fit models to
estimate the hazards for each facility and each neighborhood characteristic, after controlling for individual
characteristics. Specifically, because we were exploring the role of structural or macro-level variables in
virologic failure, each variable at the facility or neighborhood level was entered, one at a time, into a
model with all individual characteristics. Finally, two models were fitted to estimate the adjusted hazards
for 1) all individual and facility characteristics and 2) all individual and neighborhood characteristics.
Model fit was compared with a Χ2 test according to difference in -2LL and degrees of freedom (see
Appendix 7).
All analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC). Ethical approval for the
analysis was granted by the Institutional Review Boards of Lehman College of the City University of New
York and of the New York City Department of Health and Mental Hygiene.

Results
Descriptive statistics
Of 8,927 New Yorkers newly diagnosed with HIV in 2006–2010 and achieving viral suppression,
approximately three-quarters were 20-49 years old (78.9%), male (74.2%), and black or Hispanic (79.9%;
Table 3.1). Approximately half were US-born (52.7%), were men who have sex with men (46.8%), and
had CD4 counts ≥350 at suppression (49.6%). Almost one-fifth (18.2%) of the population experienced
failure within 12 months of suppression (Table 3.1). Compared to persons who did not experience failure
within 12 months of suppression, those who did were more likely to be younger, female, black or
Hispanic, born in a US dependency, and injection drug user or heterosexual (all p-values <0.001).
Virologic failure occurred at a median of 728 days, i.e., approximately 2 years after achievement
of suppression (Table 3.1). Failure happened most quickly among persons who were younger vs. older,
black or Hispanic vs. white, born in the US or a US dependency vs. foreign-born, or injection drug user
vs. other risk categories. Failure was also quicker among persons who had suppressed in later vs. earlier
calendar years (but likely, in part, as an artifact of the shorter follow-up time for those suppressing in later
years), had higher vs. lower CD4 counts at suppression, or first achieved suppression in large outpatient
facilities or large private practices vs. smaller or other facility types. Differences in time to failure were
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most prominent by CD4 count (827 days among persons with CD4 0-199 vs. 599 among 500+). These
differences were confirmed by the Kaplan-Meier survival curves (by CD4 count, p=0.0074; Figure 3.1a).
Approximately half of the population first achieved suppression in facilities that cared for ≥1,000
HIV-positive persons (52.7%), were hospitals (54.7%), and were 1 to <5 miles from their home (52.5%;
Table 3.2); and lived in neighborhoods where ≥20% of the population was below the poverty threshold
(i.e., high or very high poverty; 58.0%). Among persons in the analysis population, the mean
neighborhood-level unemployment rate was 10.7% (for reference, in comparison, the citywide rate was
9.5%[55]), and the mean neighborhood-level percent black was 33.3% (the citywide rate was 22.8%[94]).
When compared to persons who maintained suppression, those who experienced failure within
12 months of first suppression were most likely to have been first suppressed at large hospitals or small
outpatient facilities and to be residents of higher-poverty neighborhoods (Table 3.2). Differences in failure
by facility type and patient volume as well as by neighborhood poverty level were clearly apparent in
Kaplan-Meier survival curves (all p<0.0001; facility type and patient volume and neighborhood poverty
shown in Figures 3.1b-3.1c).
Modelling individual characteristics
Table 3.3 presents the unadjusted and adjusted HRs for individual characteristics on HIV virologic
failure among persons newly diagnosed with HIV and achieving viral suppression in NYC. The
unadjusted HRs show that persons who were younger, female, black or Hispanic, born in the US or a US
dependency, not men who have sex with men, and who had a CD4 count ≥500 cells/mL experienced
rates of failure that were elevated at least 10% (range 11% to 95%).
After adjustment for individual characteristics only, the rate of virologic failure remained higher
among younger persons, blacks and Hispanics, US- and US-dependency born persons, heterosexuals
and injection drug users, and persons with CD4 counts ≥500 cells/mL at suppression, compared with
others. For example, rates were between 21 and 101% higher for persons 13-49 years old relative to
those 60 and older (e.g., 20-29 years old, 56%[95%CI=1.32-1.85]). These findings remained nearly
identical when adjusting for either facility or neighborhood characteristics (adjusted hazard ratios [AHRs]
2 and 3 in Table 3.3).
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Modelling facility and neighborhood characteristics
Table 3.4 presents the unadjusted and adjusted HRs for facility and neighborhood characteristics
on HIV virologic failure among persons newly diagnosed and achieving suppression with HIV in NYC.
The unadjusted HRs show higher failure rates among persons suppressed at hospitals and small
outpatient facilities, and among residents of neighborhoods with higher proportions of residents who were
poor, unemployed, or black, compared with others.
Most facility-related findings remained the same after adjustment for individual characteristics
alone, and then individual characteristics as well as either all facility or all neighborhood characteristics.
However, persons suppressed at small private practices or at small facilities other than hospitals,
outpatient facilities, or private practices, became as likely as persons in large hospitals to experience
failure (when controlling for all individual and facility characteristics, AHR[95%CI]=0.94[0.81-1.08]). The
model with all individual- and facility-level variables had the best fit (-2LL: 64,069; p<0.0001 vs. the model
with all individual-level variables only; see Appendix 7). Among neighborhood characteristics, only high
or very high poverty remained associated with failure in models adjusted for individual characteristics
(e.g., AHR=1.19[95% CI=1.06-1.34] for very-high vs. low poverty).

Discussion
Virologic failure after suppression was experienced more quickly among persons who were
younger, black or Hispanic, US- or US-dependency-born, non-MSM, and diagnosed in earlier years, and
among persons with higher CD4 counts at suppression, after controlling for facility or neighborhood
characteristics. Similarly, persons receiving care at facilities that were not large outpatient facilities or
large private practices, and residents of higher-poverty neighborhoods, had higher failure rates than
others, after controlling for individual and other facility or neighborhood characteristics.
Our findings about individual, facility, and neighborhood characteristics associated with failure
were largely consistent with the literature [15, 31-34, 39] and also provided unique information about
teenagers. Several studies have examined the influence of age on suppression and failure among
persons 18 or 21 years of age and older.[15, 95, 96] However, few studies of virologic failure have
included younger teens. In our analysis, persons in the 13-19-year age group (28% of whom were under
18; see Appendix 7) had the highest rate of failure. Teenagers have been found to have lower rates of
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retention in care and ART adherence.[77, 78] Higher failure rates among persons in care at facilities
other than large outpatient facilities or large private practices possibly may be because those facilities
were less likely to provide services supporting retention, adherence, and case management (in some
cases, due to their smaller size), which have been shown to facilitate retention in care;[79, 80] their
providers were less likely to adhere to HIV-related care recommendations;[81] or the patients had clinical,
behavioral, or socioeconomic characteristics not captured in our models, such as addiction, other mental
illness, or individual poverty, that left them less able to maintain high adherence even if they were able to
see a physician, obtain ART, and achieve suppression. The potential explanations of individual poverty
or of mental illness (if so disabling as to qualify someone for public health insurance) would be consistent
with previous findings that persons with private insurance were more likely to sustain viral suppression
than persons insured by Medicaid or Medicare, or who were uninsured.[20] Our analysis was unable to
identify which of these factors might account for the higher failure rates among persons achieving
suppression even at large hospitals, many of which are Designated AIDS Centers. Our findings about
neighborhood-level poverty being associated with failure were consistent with previous studies on
neighborhood-level socioeconomic factors and care-related outcomes[31, 33, 38-42]. However,
percentages of neighborhood residents who were black or unemployed were not associated with failure
after controlling for neighborhood-level poverty. This is consistent with previous findings that
neighborhood-level poverty, rather than other factors such as neighborhood-level racial/ethnic makeup or
unemployment rates, was the socioeconomic indicator most predictive of health disparities.[47] This also
suggests that the many resources available for low-income PLWHA in NYC to receive care, medication,
and other forms of support, may not entirely eliminate the effects of poverty on HIV-related health
outcomes.
Prior literature found that shorter distance to the nearest HIV care site was associated with
achievement of viral suppression among persons retained in care.[84] However, we found no association
between distance from a person’s residence to the facility at which s/he was first suppressed (i.e., where
s/he was receiving care) and time from first viral suppression to failure. The extensiveness of NYC’s
systems of HIV care and public transit,[97] coupled with New York State’s generous benefits and services
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for persons with HIV,[98] may have helped render patient-provider distance irrelevant to virologic failure –
even as a relationship between neighborhood-level poverty and failure persisted.
In summary, adding facility and neighborhood variables to population-level models of virologic
failure after suppression did not change the individual characteristics associated with failure but did permit
the identification of several structural (i.e., facility and neighborhood) factors also associated with failure.
These structural factors may be useful targets for interventions aiming to increase maintenance of
suppression among persons with HIV, or may be used to indicate persons who would benefit from
additional support to maintain suppression, thereby improving their health and reducing transmissibility.
Limitations
Our analysis was subject to limitations typical of population-based, multilevel, geographic, or
surveillance-based analyses. Namely, some people’s VL was measured only at irregular intervals, and
outmigration could not be directly ascertained. Data on several factors that may influence maintenance of
suppression were not available in the HIV surveillance registry. Additionally, it was difficult to identify the
level at which certain characteristics influenced the outcome. Finally, findings may have been sensitive to
the geographic level of aggregation, i.e., Census tract, or to residential moves between diagnosis and
suppression. These factors may have caused over- or underestimation of hazard ratios.
Our analysis had VL data only when persons sought care, which was at their discretion and not
necessarily at regular intervals. Persons may have experienced virologic failure sometime before it was
measured in a VL test or after dropping out of care. Persons not in care in NYC for up to 12 months after
a suppressed VL were presumed to be present and suppressed, although prior to the 12-month mark
they may have experienced failure or moved out of NYC and maintained suppression elsewhere. It is not
clear whether irregular testing and unascertained outmigration would have increased or decreased our
hazard ratios. However, the majority of New Yorkers newly diagnosed with HIV between 2006 and 2010
were engaged in care at intervals that were both consistent with federal guidelines and sufficiently
frequent to produce population-level estimates of suppression. Specifically, among newly diagnosed
persons with at least one VL test between diagnosis and death, persons diagnosed in 2006, with the most
follow-up, had a median of 17 VL tests (IQR: 10-23) and the median interval between tests was 120 days
(4 months; IQR: 95-182 days), while persons diagnosed in 2010 had a median of 8 tests (IQR: 5-10) and
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the median interval between tests was 101 days (3 months; IQR: 85-139 days). Additionally, there is
likely to be little under-ascertainment of failure among persons in NYC, for several reasons. First, a
recently diagnosed and virally suppressed person with no subsequent blood draw for VL tests cannot
receive ART by prescription and therefore is unlikely to maintain suppression.[72] Second, a newly
suppressed person was in NYC as recently as his/her suppression date, and thus, had relatively little time
to leave NYC. Third, the system of care and services, generous benefits, and large HIV-positive
population in NYC have long made it a relatively attractive place for HIV-positive persons to live and
receive care; this likely promotes retention and suppression.
Because the HIV surveillance system provided the individual-level data in our analysis,
information about several individual factors that may influence the maintenance of suppression were not
available. Specifically, mental illness and addiction that are not well-controlled may affect a person’s
ability to adhere to ART, potentially triggering failure after suppression, but mental health and substance
use (other than injection drug use) are not necessarily well-documented in the medical record at the
facility diagnosing HIV nor well-ascertained by surveillance. Further, information about ART adherence,
the primary driver of maintenance of suppression, was not available.
Characteristics measured at one level in our models may have acted at another level. For
example, poverty was measured at the neighborhood level only and was found to be significantly
associated with virologic failure. It is possible that this association was present only because there is an
association between neighborhood- and individual-level poverty, which was not measured, and failure
(and individual- and neighborhood-level poverty are correlated), or alternatively, that individual-level
poverty would not in fact have been associated with failure. This limitation is not unique to our analysis
but rather is characteristic of multilevel analyses.[89, 90]
As in any geographic analysis, our findings may have been subject to the modifiable areal unit
problem, meaning they were sensitive to the geographic level (Census tract) at which patient residence
and facility location were measured.[99-101] Analyses at other levels would have grouped people
differently, e.g., in smaller or larger areas, or with different geographic boundaries that would have
resulted in different aggregations of people, and may have produced different findings. Further, because
of the edge effect, adjacent or nearby Census tracts may have had cross-boundary similarities and
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influences, largely due to the movement of people across multiple Census tracts.[102, 103] This could
dilute the effect of differences across neighborhoods.
Because Census tract-level residence information at first viral suppression was not available, we
assumed that the neighborhood characteristics of a person’s residence at diagnosis were comparable to
those at first suppression. However, more than 21% of persons in our analysis may have changed
Census tract of residence between diagnosis and suppression. Studies have shown that persons who
move typically go to similar neighborhoods.[104] However, in the population in our analyses, many of the
21% who moved went to Census tracts with different characteristics, e.g., poverty level, than the Census
tracts they were living in at diagnosis. It is not possible to determine whether this misclassification of
persons’ neighborhood-level variables was differential or non-differential (see Appendix 7).
Strengths
This is among the first analyses in the US to investigate the influence of facility and neighborhood
on HIV outcomes using surveillance data. [31, 33, 35, 87] The data were drawn from population
surveillance in the largest HIV epidemic in the US, in a diverse US city. The analysis combined data from
multiple sources to assess the potential influence on virologic failure of factors beyond the individual.
Mandatory electronic reporting of laboratory tests in NYC provided information about all measured VLs for
all HIV-positive persons receiving care in NYC, as opposed to in a clinical trials environment, where
findings can differ from those in a population setting. To assign area-based characteristics to individuals,
we used patient address geocoded to the Census tract, which is the gold standard for detection of public
health disparities;[47] other geographic analyses of HIV care outcomes have used only counties and ZIP
codes, which are much larger than Census tracts. Due to NYC’s heterogeneity, the smaller geographic
unit (tract) was preferable. We filled a gap in the literature by including teenagers, who are subject to the
same treatment guidelines as adults but whose age may have contributed to quicker virologic failure than
among older persons.[78] The survival analysis method permitted the analysis of VL data over a long
period of time and did not require multiple VL tests as an inclusion criterion.
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Conclusions
Our findings suggest that persons with HIV who are younger, black or Hispanic, US- or USdependency-born, non-MSM, or have higher CD4 counts at suppression; who seek care at facilities other
than large outpatient facilities or large private practices; or who live in high- or very-high-poverty
neighborhoods; were more likely to experience virologic failure. These populations may need more
assistance after viral suppression in the areas of retention in care or ART adherence. These facility- and
neighborhood-level effects were found even in NYC, the setting for this analysis, i.e., a large, densely
populated city with extensive systems of high-quality HIV care, social services, and public transportation.
It is possible that the effects would have been even larger in a setting other than NYC that may not have
been as well-resourced vis-à-vis medical facilities and transportation systems. It is possible that residents
of poorer neighborhoods in NYC might benefit from even better care that permitted them to maintain
suppression at comparable rates as residents of wealthier neighborhoods; rectifying this disparity may
require targeted adherence support services or additional general poverty alleviation. Further
investigation is needed to understand why lower rates of failure were seen among patients at large
outpatient facilities and large private providers, which serve a minority of New Yorkers with HIV.
Additional investigation would also be valuable to suggest how large hospitals – many of which are
Designated AIDS Centers, and which detected the first viral suppression for 43% of newly diagnosed
New Yorkers – can better support their patients in maintaining suppression.
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Table 3.1. HIV virologic failure1 within 12 months after first viral suppression among persons newly diagnosed with HIV in
New York City in 2006-2010 and followed through 2012, by individual-level characteristics
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Total
Age group (years)
13 - 19
20 - 29
30 - 39
40 - 49
50 - 59
≥60
Sex at birth
Male
Female
Race/Ethnicity
Black
Hispanic
White
Other
Country of birth
US
US Dependency
Foreign
Unknown

Total

No virologic
failure* within
12 months of
suppression

Distribution (n)
100.0 (8,927)

Distribution (n)
100.0 (7,300)

Virologic failure1 within 12 months of
suppression
Distribution (n)
100.0 (1,627)

Prevalence
18.2

p-value2

Median time from
suppression to failure
Median
(IQR3) days
728 (864)

<0.0001
2.2 (196)
26.4 (2,360)
27.0 (2,409)
25.5 (2,274)
13.8 (1,235)
5.1 (453)

1.8 (134)
25.8 (1,887)
27.5 (2,009)
25.6 (1,866)
14.2 (1,036)
5.0 (368)

3.8 (62)
29.1 (473)
24.6 (400)
25.1 (408)
12.2 (199)
5.2 (85)

31.6
20.0
16.6
17.9
16.1
18.8

74.2 (6,623)
25.8 (2,304)

75.6 (5,518)
24.4 (1,782)

67.9 (1,105)
32.1 (522)

16.7
22.7

<0.0001
571 (746)
653 (748)
770 (887)
741 (904)
801 (940)
796 (989)

<0.0001

0.0564
742 (841)
708 (930)

<0.0001
46.7 (4,167)
33.2 (2,964)
16.7 (1,489)
3.4 (307)

45.6 (3,330)
32.4 (2,362)
18.4 (1,341)
3.7 (267)

51.4 (837)
37.0 (602)
9.1 (148)
2.5 (40)

20.1
20.3
9.9
13.0

52.7 (4,703)
4.5 (404)
32.6 (2,906)
10.2 (914)

52.5 (3,829)
4.1 (302)
32.9 (2,402)
10.5 (767)

53.7 (874)
6.3 (102)
31.0 (504)
9.0 (147)

18.6
25.2
17.3
16.1

p-value4

<0.0001
685 (865)
732 (918)
807 (749)
908 (870)

0.0004

<0.0001
689 (823)
685 (959)
791 (913)
818 (981)
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HIV transmission risk
Men who have sex
with men
Injection drug use
history
Heterosexual
Other or unknown
Year of suppression
2006
2007
2008
2009
2010
2011
2012
CD4 count at
suppression
0-199
200-349
350-499
500+
No CD4 count

<0.0001

<0.0001

46.8 (4,181)

48.8 (3,561)

38.1 (620)

14.8

753 (808)

4.7 (423)

4.2 (307)

7.1 (116)

27.4

550 (975)

26.1 (2,328)
22.3 (1,995)

24.9 (1,815)
22.2 (1,617)

31.5 (513)
23.2 (378)

22.0
18.9

711 (900)
748 (946)

6.1 (549)
12.7 (1,131)
16.6 (1,478)
20.2 (1,803)
22.7 (2,030)
14.5 (1,291)
7.2 (645)

6.0 (441)
12.2 (894)
16.4 (1,195)
20.1 (1,468)
23.3 (1,699)
14.1 (1,029)
7.9 (574)

6.6 (108)
14.6 (237)
17.4 (283)
20.6 (335)
20.3 (331)
16.1 (262)
4.4 (71)

19.7
21.0
19.1
18.6
16.3
20.3
11.0

<0.0001

<0.0001
1,077 (1,869)
1,255 (1,577)
1,241 (1,225)
1,138 (836)
809 (451)
516 (264)
194 (188)

0.4633
19.3 (1,722)
22.5 (2,006)
22.5 (2,012)
27.1 (2,415)
8.6 (772)

19.0 (1,390)
22.5 (1,641)
22.8 (1,664)
26.9 (1,964)
8.8 (641)

20.4 (332)
22.4 (365)
21.4 (348)
27.7 (451)
8.1 (131)

1

Virologic failure was defined as first viral load of ≥1,000/mL or 12 months without a viral load test.

2

p-value: Chi-square test of association between each variable and virologic failure

3

IQR: Interquartile range, i.e., 3rd quartile minus 1st quartile

4

p-value: Mann-Whitney U test of differences by each variable in median days to failure

19.3
18.2
17.3
18.7
17.0

<0.0001
827 (1,089)
816 (941)
768 (836)
599 (674)
718 (922)

Table 3.2. HIV virologic failure1 after suppression among persons newly diagnosed with HIV in New York City in 20062010 and followed through 2012, by characteristics of the health care facility at which persons were diagnosed and the
neighborhood (Census tract) persons were living in at diagnosis

Total
Distribution
(n) or Mean
(SD)

No virologic
failure* within 12
months of
suppression

Distribution (n)

1

Virologic failure within 12 months of
suppression

Distribution (n)

Prevalence

p-value2

Median time from
suppression to
failure
Median
(IQR3)
days p-value4
728 (864)
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Total
Facility-level variables
Number of HIV-positive
patients cared for
annually by health care
facility where patient
suppressed (patient
volume)
<250
250 to 999
1,000 to 1,999
≥2,000
Type of facility where
patient suppressed
Hospital
Outpatient
Private physician

100.0 (8,927)

100.0 (7,300)

100.0 (1,627)

18.2

0.1007

21.9 (1,951)
25.4 (2,267)
26.2 (2,342)
26.5 (2,367)

21.9 (1,596)
25.7 (1,874)
25.7 (1,877)
26.8 (1,953)

21.8 (355)
24.2 (393)
28.6 (465)
25.4 (414)

18.2
17.3
19.9
17.5

0.2227

711 (831)
731 (833)
742 (931)
748 (857)
<0.0001

54.7 (4,879)
25.7 (2,298)
17.5 (1,564)

53.5 (3,904)
25.5 (1,864)
19.0 (1,386)

59.9 (975)
26.7 (434)
10.9 (178)

20.0
18.9
11.4

<0.0001
741 (925)
678 (789)
815 (817)
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Other or unknown
Facility type by patient
volume
Hospital, ≥1,000
Hospital, <1,000
Outpatient, ≥1,000
Outpatient, <1,000
Private physician,
≥1,000
Private physician,
<1,000
Other or unknown,
<1,000
Distance between
patient and facility
<1 mile
1 to <5 miles
5 to <10 miles
≥10 miles
Neighborhood-level
variables
Percent of population
below federal poverty
threshold in past 12
months
Low (<10%)
Medium (10 to <20%)
High (20 to <30%)
Very high (≥30%)
Percent of population 16
years and over that was
unemployed in past week

2.1 (186)

2.0 (146)

2.5 (40)

21.5

578 (746)
<0.0001

<0.0001

43.3 (3,865)
11.4 (1,014)
8.3 (738)
17.5 (1,560)

42.1 (3,074)
11.4 (830)
9.0 (655)
16.6 (1,209)

48.6 (791)
11.3 (184)
5.1 (83)
21.6 (351)

20.5
18.1
11.2
22.5

732 (936)
761 (887)
739 (691)
645 (824)

1.2 (106)

1.4 (101)

0.3 (5)

4.7

977 (714)

16.3 (1,458)

17.6 (1,285)

10.6 (173)

11.9

794 (814)

2.1 (186)

2.0 (146)

2.5 (40)

21.5

578 (746)
0.0925

15.8 (1,409)
52.5 (4,684)
22.7 (2,024)
9.1 (810)

15.5 (1,134)
52.5 (3,830)
23.1 (1,687)
8.9 (649)

16.9 (275)
52.5 (854)
20.7 (337)
9.9 (161)

19.5
18.2
16.7
19.9

0.1522
724 (881)
740 (869)
741 (839)
684 (857)

<0.0001
15.9 (1,420)
26.1 (2,328)
25.5 (2,278)
32.5 (2,901)

17.0 (1,238)
26.8 (1,956)
25.4 (1,854)
30.8 (2,252)

11.2 (182)
22.9 (372)
26.1 (424)
39.9 (649)

12.8
16.0
18.6
22.4

10.7 (5.6)

-

-

-

<0.0001
832 (850)
750 (827)
726 (850)
658 (913)

N/A

-

N/A

Percent of population
that is black or African
American only (nonHispanic)

33.3 (29.0)

-

-

1

Virologic failure was defined as first viral load of ≥1,000/mL or 12 months without a viral load test.

2

p-value: Chi-square test of association between each variable and virologic failure

3

IQR: Interquartile range, i.e., 3rd quartile minus 1st quartile

4

p-value: Mann-Whitney U test of differences by each variable in median days to failure

-

N/A

-

N/A
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Table 3.3. Proportional hazards regressions of HIV virologic failure1 after suppression among persons newly diagnosed
with HIV in New York City in 2006-2010 and followed through 2012 (N=8,927), by individual-level characteristics
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Age group (years)
13 – 19
20 – 29
30 – 39
40 – 49
50 – 59
≥60
Sex at birth
Male
Female
Race/Ethnicity
Black
Hispanic
White
Other
Country of birth
US
US Dependency
Foreign
Unknown
HIV transmission risk
Men who have sex with men
Injection drug use history

HR
(95% CI)1

AHR 1
(95% CI)1,2

AHR 2
(95% CI)1,3

AHR 3
(95% CI)1,4

1.95 (1.52-2.49)
1.35 (1.14-1.59)
1.10 (0.93-1.29)
1.11 (0.93-1.31)
0.97 (0.81-1.16)
1.00

2.01 (1.57-2.57)
1.56 (1.32-1.85)
1.27 (1.08-1.50)
1.21 (1.02-1.43)
0.98 (0.82-1.17)
1.00

2.00 (1.53-2.62)
1.61 (1.33-1.93)
1.32 (1.10-1.58)
1.24 (1.04-1.47)
0.99 (0.83-1.17)
1.00

1.97 (1.53-2.52)
1.54 (1.31-1.82)
1.26 (1.07-1.49)
1.20 (1.02-1.42)
0.97 (0.81-1.17)
1.00

0.82 (0.76-0.89)
1.00

1.06 (0.95-1.19)
1.00

1.07 (0.98-1.17)
1.00

1.08 (0.96-1.20)
1.00

1.54 (1.41-1.69)
1.35 (1.22-1.49)
1.00
0.89 (0.72-1.10)

1.39 (1.26-1.53)
1.24 (1.11-1.39)
1.00
0.92 (0.74-1.15)

1.31 (1.16-1.47)
1.17 (1.02-1.35)
1.00
0.87 (0.65-1.18)

1.27 (1.14-1.43)
1.17 (1.04-1.31)
1.00
0.90 (0.72-1.12)

1.19 (1.10-1.28)
1.38 (1.19-1.60)
1.00
0.95 (0.84-1.06)

1.18 (1.09-1.28)
1.40 (1.20-1.65)
1.00
1.01 (0.90-1.15)

1.19 (1.10-1.28)
1.39 (1.19-1.64)
1.00
1.01 (0.88-1.16)

1.17 (1.08-1.27)
1.36 (1.16-1.60)
1.00
1.02 (0.90-1.15)

0.75 (0.69-0.81)
1.22 (1.05-1.42)

0.72 (0.64-0.81)
1.23 (1.05-1.46)

0.75 (0.67-0.84)
1.23 (1.06-1.41)

0.73 (0.65-0.83)
1.23 (1.04-1.45)
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Heterosexual
Other or unknown
Year of suppression
2006
2007
2008
2009
2010
2011
2012
CD4 count at suppression
0-199
200-349
350-499
500+
No CD4 count

1.00
0.87 (0.79-0.95)

1.00
0.89 (0.80-0.99)

1.00
0.90 (0.81-1.00)

1.00
0.89 (0.80-0.99)

1.17 (0.90-1.51)
1.16 (0.91-1.49)
1.10 (0.86-1.40)
0.98 (0.77-1.25)
0.94 (0.74-1.20)
1.00 (0.78-1.29)
1.00

1.21 (0.93-1.57)
1.21 (0.94-1.55)
1.15 (0.90-1.46)
1.01 (0.79-1.29)
0.98 (0.77-1.25)
1.05 (0.81-1.34)
1.00

1.21 (0.94-1.56)
1.20 (0.93-1.54)
1.14 (0.89-1.46)
1.00 (0.80-1.26)
0.98 (0.77-1.26)
1.05 (0.83-1.34)
1.00

1.22 (0.94-1.58)
1.21 (0.94-1.56)
1.16 (0.91-1.47)
1.02 (0.80-1.30)
0.99 (0.78-1.27)
1.05 (0.82-1.35)
1.00

1.00
0.97 (0.88-1.07)
0.94 (0.85-1.04)
1.11 (1.01-1.22)
0.99 (0.87-1.13)

1.00
0.99 (0.89-1.09)
0.97 (0.88-1.08)
1.15 (1.04-1.27)
0.98 (0.86-1.12)

1.00
1.00 (0.89-1.11)
0.99 (0.86-1.14)
1.17 (1.05-1.30)
0.98 (0.88-1.10)

1.00
0.99 (0.89-1.09)
0.98 (0.88-1.08)
1.15 (1.04-1.27)
0.98 (0.86-1.12)

1

Virologic failure was defined as first viral load of ≥1,000/mL or 12 months without a viral load test. Hazard ratios and confidence intervals for models with
only individual- or neighborhood-level variables account for clustering by Census tract, and those with facility-level variables account for clustering by facility
where suppression was achieved. Hazard ratios (HR) are unadjusted unless indicated as “AHR.”
2

Adjusted hazard ratio 1: For each individual-level variable, adjusting for all other individual-level variables

3

Adjusted hazard ratio 2: For all individual-level variables, adjusting for all facility-level variables

4

Adjusted hazard ratio 3: For all individual-level variables, adjusting for all neighborhood-level variables

Table 3.4. Proportional hazards regressions of HIV virologic failure1 after suppression among persons newly diagnosed
with HIV in New York City in 2006-2010 and followed through 2012 (N=8,927), by characteristics of the health care facility
at which persons were diagnosed and the neighborhood (Census tract) persons were living in at diagnosis
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Facility-level variables
Facility type by patient volume
Hospital, ≥1,000
Hospital, <1,000
Outpatient, ≥1,000
Outpatient, <1,000
Private physician, ≥1,000
Private physician, <1,000
Other or unknown, <1,000
Distance between patient and facility
<1 mile
1 to <5 miles
5 to <10 miles
≥10 miles
Neighborhood-level variables
Percent of population below federal poverty
threshold in past 12 months
Low (<10%)
Medium (10 to <20%)
High (20 to <30%)
Very high (≥30%)

HR
(95% CI)1

AHR 1
(95% CI)1,2

AHR 2
(95% CI)1,3

1.00
0.97 (0.87-1.08)
0.56 (0.48-0.65)
1.17 (1.07-1.28)
0.66 (0.50-0.88)
0.81 (0.73-0.89)
1.16 (0.92-1.45)

1.00
0.98 (0.87-1.11)
0.62 (0.52-0.74)
1.17 (1.03-1.34)
0.84 (0.75-0.94)
0.94 (0.81-1.08)
1.26 (1.00-1.59)

1.00
0.98 (0.87-1.11)
0.63 (0.53-0.75)
1.17 (1.03-1.33)
0.84 (0.75-0.94)
0.94 (0.81-1.08)
1.28 (1.01-1.62)

1.00
0.99 (0.92-1.07)
0.91 (0.80-1.02)
1.01 (0.86-1.18)

1.00
0.96 (0.89-1.05)
0.90 (0.80-1.01)
0.94 (0.80-1.10)

1.00
0.98 (0.90-1.07)
0.94 (0.85-1.04)
0.96 (0.83-1.11)

1.00
1.17 (1.05-1.30)
1.35 (1.21-1.50)
1.49 (1.34-1.64)

1.00
1.12 (1.00-1.24)
1.19 (1.07-1.33)
1.23 (1.11-1.37)

AHR 3
(95% CI)1,4

1.00
1.11 (0.99-1.23)
1.17 (1.04-1.31)
1.19 (1.06-1.34)

Percent of population 16 years and over that was
unemployed in past week5

1.22 (1.15-1.30)

1.09 (1.02-1.17)

1.04 (0.96-1.12)

Percent of population that is black or African
American only (non-Hispanic)5

1.04 (1.03-1.05)

1.01 (1.00-1.02)

1.01 (1.00-1.02)

1

Virologic failure was defined as first viral load of ≥1,000/mL or 12 months without a viral load test. Hazard ratios and confidence intervals for facility-level
variables account for clustering by facility where suppression was achieved, and those for neighborhood-level variables account for clustering by Census
tract. Hazard ratios (HR) are unadjusted unless indicated as “AHR.”
2
Adjusted hazard ratio 1: For each facility- or neighborhood-level variable, adjusting for all individual-level variables
3
4

Adjusted hazard ratio 2: For all facility-level variables, adjusting for all individual-level and all other facility-level variables

Adjusted hazard ratio 3: For all neighborhood-level variables, adjusting for all individual-level and all other neighborhood-level variables
Hazard ratios presented for continuous variables (percent unemployed and percent black) represent the risk per 10-percentage-point increase in the
variable.
5
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Figure 3.1. Kaplan-Meier survival curves of maintenance of HIV viral suppression after
first viral suppression among persons newly diagnosed with HIV in New York City in
2006-2010 and followed through 2012

Figure 3.1a. By CD4 count (cells/mL) at suppression (p<0.01)
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Figure 3.1b. By facility type and annual patient volume (number of HIV-positive persons seen by
facility where first HIV viral suppression occurred, in year of person’s first suppression) (p<0.01)

Figure 3.1c. By neighborhood poverty (percent of residents with incomes under the federal
poverty threshold) (p<0.01)
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Chapter 4. The association of perceived neighborhood social cohesion with
achievement of HIV viral suppression among persons recently diagnosed with
HIV and interviewed in New York City
Introduction
New York City (NYC) is home to more than 7% of all persons newly diagnosed with HIV in the
United States (US) each year.[1, 2]. It is recommended that persons newly diagnosed with HIV have their
viral load (VL) measured as soon as they begin HIV-related medical care and then at least every six
months.[3] Acute HIV infection typically is followed by a very high VL (e.g., >100,000 copies of HIV RNA
per milliliter of blood) that eventually declines to lower levels that vary by individual. Further reduction of
HIV VL to low or undetectable levels (e.g., ≤400 copies/mL) is referred to as viral suppression. Although
a small percentage of persons (i.e., “elite controllers”) is able to achieve suppression without treatment,
most persons achieve suppression through treatment with antiretroviral therapy (ART).[4] Provided that
the virus is sensitive to the multi-drug regimen chosen and the person is adherent, suppression is
achieved quickly (within 24 weeks) and durably.[5, 6]
Viral suppression not only slows progression of HIV disease [7] but also reduces the likelihood of
onward sexual transmission.[8] As few as 20% of PLWHA were thought to be suppressed in the US in
the early 2000s, while today most estimates exceed 50%;[10-14] in NYC, it was 59% in 2010.[14] In
2010, the US National HIV/AIDS Strategy set as a goal a 20% increase by 2015 in the proportion of
persons in populations most affected by HIV (blacks, Hispanics, and gay and bisexual men) who are
virally suppressed.[9] Updated national HIV treatment guidelines now recommend that all persons with
HIV be offered ART.[3] However, until recently, it was recommended that persons begin ART only once
immunocompromised, making immune status the key factor in treatment decisions. Although retention in
care and ART are the main drivers of viral suppression, more rapid achievement of suppression has also
been associated with individual-level demographic characteristics (e.g., older age,[13, 15, 20] male
sex,[21-23] and non-black racial/ethnic category [13, 24-28]), and baseline clinical status indicators (e.g,
CD4 count and VL[15, 29, 30]).
Studies focusing on individual-level factors affecting viral suppression may benefit from the
addition of social and structural variables that have previously been associated with health and health-
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seeking behavior, such as perceived neighborhood social cohesion. Lower perceived neighborhood
social cohesion has been associated with lower primary care use among older urban adults.[44] Lower
care use may, in turn, influence the time from HIV diagnosis to viral suppression because ART and VL
testing are offered exclusively in the context of medical care visits. Low cohesion has also been
associated with lower condom use and higher sexually transmitted infection (STI) rates among urban
adolescents and young adults.[45, 46] Because STI can increase VL, social cohesion may affect viral
suppression through condom use and STI rates. However, the association of social cohesion with HIV
outcomes has not been examined. The availability of data on social cohesion for a sample of New
Yorkers recently diagnosed with HIV allows the investigation of the effect of perceived neighborhood
social cohesion on achievement of viral suppression among NYC residents who were diagnosed with HIV
between 2006 and 2012 at ≥13 years of age. Findings could potentially be helpful in the development of
interventions to increase suppression rates by accounting for a person’s perception of neighborhood
social cohesion and determining which persons may need additional support to achieve suppression.

Methods
Data sources
This retrospective analysis used data from the NYC HIV surveillance registry, the NYC arm of the
CDC-coordinated Case Surveillance-Based Sampling project (CSBS),[53] and the 2007-2011 American
Community Surveys.[55] The surveillance registry includes all persons diagnosed and reported with HIV
in NYC since 2000 and all persons with AIDS since 1981. It gathers information by medical record
review, provider report at diagnosis, personal interviews with patients, and HIV-related laboratory tests,
which are electronically reported to surveillance for all cases receiving diagnosis and/or care in NYC.
Individual-level data acquired from the registry included demographic and clinical information collected at
the time of first report, ZIP code of residence at diagnosis, and HIV-related laboratory test results from
January 1, 2006, to June 30, 2014. Laboratory reports contain the test type, specimen collection date,
result, and submitting provider or facility. Reports on existing cases are added to their registry record;
reports not matching an existing case are sent out for field investigation to confirm the diagnosis and
collect other required data. All registry data used in this analysis were reported as of September 30,
2014, allowing a three-month reporting lag for laboratory tests performed through June 30, 2014.
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CSBS was a surveillance activity that involved conducting in-person interviews and medical
record reviews for a stratified random sample of persons from the registry. It was a three-year, multisite
demonstration pilot project coordinated by the CDC. CSBS used the HIV surveillance system to draw a
sample of HIV-diagnosed adults that would include persons out of care as well as persons in care. As of
2015, the CDC’s Medical Monitoring Project had adopted the CSBS sampling method.
CSBS data are stored outside of the HIV surveillance registry. Data from CSBS used for this
analysis included individual-level information on household income, number of persons who depended on
that income (a proxy for family size), highest educational level completed, and three questions
aggregated to develop an index of perceived neighborhood social cohesion, as has been done
previously.[45, 46] These CSBS variables were obtained from the interview portion of the 2012-2014
cycles of the study and recorded in the CSBS database by April 15, 2015.
Finally, neighborhood poverty statistics at the level of ZIP code tabulation area (ZCTA) were
acquired from the 2011 American Community Survey 5-year estimates based on the 2007-2011 surveys.
ZIP codes are a system of delineating areas for postal service, and most people know the ZIP code of
their residence, while ZCTAs are geographic areas used by the American Community Survey as close
geographic approximations of ZIP codes.[105] ZIP codes, which in NYC are typically larger than Census
tracts but smaller than congressional districts and counties, were the smallest readily available
geographic unit of analysis. Neighborhood poverty statistics were linked to cases through the ZIP code of
patient residence at diagnosis.
Population
CSBS sampled 800 persons from the HIV surveillance registry across three annual sample cycles
(200 persons in the 2012 cycle, 300 in 2013, and 300 in 2014). Each cycle’s sample was stratified by
diagnosis year to oversample persons diagnosed in more recent years and limited to persons ≥18 years
of age as of the sample date. NYC residents who were interviewed for CSBS in 2012-2014, newly
diagnosed with HIV between 2006 and 2012, and ≥13 years of age at diagnosis (which was potentially
several years prior to the sample date) were eligible for the analysis. However, among the 294 persons
located and interviewed for CSBS in 2012-2014, many were excluded: those who were not newly
diagnosed with HIV between 2006 and 2012 and ≥13 years of age at diagnosis (n=152), did not have an
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NYC ZIP code of residence at diagnosis (n=9), died within 31 days after diagnosis (n=0), did not have a
Western blot confirmatory test within 31 days post-diagnosis and were not diagnosed during acute HIV
infection (i.e., their true diagnosis date was uncertain; n=6), had a suppressed (≤400 copies/mL) viral load
≤31 days after diagnosis (which suggests a misclassified diagnosis date; n=11), or did not respond to all
three questions about perceived neighborhood social cohesion (n=24). These exclusions yielded an
analytical sample of 92 persons (see Appendix 2).
Outcome
The outcome of interest was the first suppressed VL (≤400 copies of HIV RNA/mL plasma) after
HIV diagnosis. The cut-off was 400 copies/mL because this was the highest lower detectable limit of all
VL assays in use during the study period.[59] Persons were censored at death or the end of the follow-up
period, whichever came earlier. Follow-up time was calculated as the number of days from the date of
HIV diagnosis to suppression, death, or 6/30/2014, whichever came first. There was no minimum
required follow-up time. In addition to measuring this outcome as time-to-event, it was also measured
dichotomously as having or not having achieved suppression within 12 months of diagnosis.
Treatment guidelines evolved during the analysis period but recommended that VL tests were
conducted 2-4 times per year after HIV diagnosis. However, some persons with HIV may have had
infrequent or no VL tests after diagnosis, because they were never linked to HIV-related medical care,
they sought care infrequently, or their physician did not test their VL at every care visit. Any persons not
known to be dead and with no suppressed VL (including persons with infrequent or no VL tests) were
presumed not to be suppressed and contributed follow-up time as long as they were alive.
Independent variable
Perceived neighborhood social cohesion was calculated from participant agreement with three
statements in the CSBS interview about trust, closeness, and helpfulness between neighbors, using a
scored 1-4 Likert scale (see Appendix 8). [45, 46] Responses were summed to yield a score ranging
from 3 to 12. Scores were dichotomized near the median, a natural break, placing approximately
equivalent numbers of persons in each category.[46] The majority of scores were 6, 9, or 12 (>20%
each), and 48% of persons had scores of 3-8 (see Appendix 8 for additional details, including results of
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our analyses were cohesion to have been classified as a three-level variable). Perceived neighborhood
social cohesion was classified as low for persons with scores of 9-12 and high for persons with scores of
3-8; lower scores indicated agreement with positive statements about the neighborhood.
Covariates
Individual characteristics and neighborhood poverty were treated as potential confounders based
on previous studies.[15, 31, 33] Demographic characteristics (age, sex at birth, race/ethnicity, country of
birth), HIV transmission risk (also referred to as transmission category), diagnosis date, viral loads, CD4
counts, and ZIP code of residence at diagnosis for calculation of neighborhood-level poverty were
extracted from the NYC HIV surveillance registry. Estimated poverty status (at the individual/family level,
based on household income) was calculated from CSBS data.
Age at HIV diagnosis was calculated from birth date and date of diagnosis and dichotomized as
13-29 years old and 30+.[2] Sex at birth was classified as male or female. Race (white or Caucasian,
black or African American, Asian or Pacific Islander, and Native American) and ethnicity (Hispanic, nonHispanic, or unknown) were collected through two questions and combined into a single variable that was
dichotomized as: black or Hispanic, and other for those of other race/ethnicity. Country of birth was
collected as country of birth when available or region of birth and categorized as born in the US or a US
dependency (e.g., Puerto Rico), or a foreign country.
HIV transmission risk category was based on the self-reported pre-diagnosis risk behaviors of the
case (e.g., injection drug use, male-male sex) and the sex, HIV status (e.g., HIV-positive), and risk (e.g.,
injection drug use) of the pre-diagnosis heterosexual sex partners reported by the person (which could
indicate high-risk heterosexual risk).[69] This information was combined into hierarchical, mutually
exclusive categories for the case: injection drug use (IDU), men who have sex with men (MSM),
heterosexual sex, and other or unknown (which included perinatal transmission),[15] and these
categories were then combined into three final groups: MSM, heterosexual, or other or unknown (which
included injection drug users). To be classified as a heterosexual male or female, persons must have
reported pre-diagnosis sex with a partner of the other sex who was HIV-infected, had injected drugs, or
had received blood products. In addition, females only could be classified as heterosexual if they had
probable heterosexual transmission noted in their medical record, reported sex with a male and no history
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of drug injection, or had any one of several behaviors associated with heterosexual transmission: history
of prostitution, multiple sex partners, sexually transmitted disease, crack/cocaine use, or sex with a
bisexual male.[2]
For analytic purposes, the year of diagnosis was determined from the earlier of physician
diagnosis date or positive Western blot test result and grouped as 2006-2009 and 2010-2012. These
were two approximately equal groups of years divided at a point when suppression became more likely
for everyone because of new HIV drug approvals and updated guidelines that encouraged earlier
treatment initiation; also, few CSBS participants (n=6) were diagnosed in 2006 or 2007. CD4 count (if
any) at diagnosis (i.e., within 3 months of diagnosis) and year of diagnosis vis-à-vis treatment guidelines
were used to estimate treatment eligibility and as a proxy for receipt of ART, on the presumption that the
majority of persons reaching the federal treatment threshold would receive ART. Treatment-eligible
persons included those diagnosed in 2006-2007 with CD4<200, diagnosed in 2008-2009 with CD4<350,
or diagnosed in 2010-2012 with CD4<500, reflecting changing treatment guidelines that increased the
CD4 count at which ART initiation was recommended.[70-72] All other persons, including those with no
reported CD4 counts, were not known to be eligible and were classified as not eligible.
Analyses included neighborhood-level poverty, defined as percent of residents in a ZIP code with
incomes under the federal poverty threshold, from 2011 American Community Survey 5-year
estimates.[74] We used this source because the 2010 decennial census did not collect poverty
information, and because ZIP code of residence was collected (by the surveillance registry) at diagnosis.
For those reasons, the 2011 American Community Survey 5-year estimates had the largest overlap with
the diagnosis period (2006-2012). Because lower neighborhood-level socioeconomic status (SES) may
be associated with both perceived neighborhood social cohesion and viral suppression, it was controlled
for when exploring the relationship between perceived neighborhood social cohesion and suppression.
The neighborhood poverty measure that we used has been associated with HIV and STI incidence and
prevalence and HIV outcomes in the US and Canada.[31, 33, 39, 40, 47, 75] Neighborhood poverty was
specified as <20% (i.e., <20% of residents had incomes below the federal poverty threshold; these were
low- or medium-poverty neighborhoods) or ≥20% (high- or very-high-poverty), based on the four-category
classification used by the NYC health department that this analysis collapsed into two categories.[76]
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Estimated poverty status (at the individual/family level) was calculated based on responses in
CSBS to questions about household income (which was collected in intervals) and number of persons
who depended on that income. These were compared with US Census Bureau weighted average
poverty thresholds for 2013 by size of family unit, and then classified as below the poverty threshold (and
thus “poor”) or above (“non-poor”) (see Appendix 9 for details).[106]
Statistical analysis
Descriptive statistics for selected individual and neighborhood characteristics were calculated and
presented for the overall population and according to suppression status within 12 months of diagnosis.
Significance of associations between each variable and achievement of suppression within 12 months
was assessed using Chi-square tests. The Mann-Whitney U test was used to ascertain differences in
median days to suppression by the end of the follow-up period. The Spearman correlation coefficient was
obtained to assess whether the dichotomized variable of perceived neighborhood social cohesion and
neighborhood-level poverty were too correlated (i.e., r>0.5) to be in the same model.
Kaplan-Meier curves showing the number of days from diagnosis to suppression were generated
by key individual and neighborhood characteristics, and log-rank tests were used to measure differences
between groups.
We used Cox proportional hazards regressions to estimate the association of individual and
neighborhood factors with suppression in crude and adjusted models. Because of the small sample size,
we did not account for correlations of individual outcomes within neighborhood (ZIP code).[62, 63]
Unadjusted models were fitted to estimate the unadjusted hazards of viral suppression for each individual
and neighborhood characteristic. In addition, several multivariable models were fitted, striving for
parsimony given the small sample size. Our final model included age at HIV diagnosis, sex at birth,
race/ethnicity, year of HIV diagnosis, and ART eligibility, for consistency with previous models of viral
suppression,[15] as well as perceived neighborhood social cohesion and neighborhood-level poverty.
All analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC). Ethical approval for these
analyses was provided by the Institutional Review Boards of Lehman College of the City University of
New York and of the NYC Department of Health and Mental Hygiene.
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Results
Descriptive statistics
Of 92 New Yorkers newly diagnosed with HIV in 2006–2012 and interviewed by CSBS,
approximately three-quarters were male (72.8%), and black or Hispanic (82.6%; Table 4.1). More than
half were ≥30 years old (66.3%), born in the US or a US dependency (68.5%), MSM (51.1%), diagnosed
in 2010-2012 (54.3%), not eligible to receive treatment based on CD4 count and diagnosis year (53.3%),
poor (60.9%), perceiving low neighborhood social cohesion (52.2%), and residents of high- or very-highpoverty neighborhoods (57.6%).
Sixty-five percent of the population achieved suppression within 12 months of diagnosis (Table
4.1). Suppression rates at 12 months were lower among persons who were younger (45.2% of persons
13-29 years old achieved suppression vs. 75.4% of persons ≥30), black or Hispanic (59.2% vs. 93.8%),
born in the US or a US dependency (57.1% vs. 82.8%), and not eligible for treatment (46.9% vs. 86.0%;
all p-values<0.05). Differences in suppression at 12 months between persons reporting low cohesion
(60.4%) and high cohesion (70.5%) were not significant (p=0.31).
Almost the entire population (95.7%) achieved viral suppression by 6/30/2014 (not shown), in a
median of 180 days (Table 4.1). Suppression happened least quickly among persons who were younger
(median=377 days), black or Hispanic (203 days), born in the US or a US dependency (218 days), not
known to be eligible for treatment (372 days), or who had low perceived neighborhood social cohesion
(204 days; all p-values <0.05). Differences were most prominent by age (median=164 days among
persons ≥30 years old vs. 377 days among 13-29) and treatment eligibility (159 days among eligible vs.
372 days among not eligible). Kaplan-Meier survival curves demonstrated the lack of difference in
achievement of suppression between persons with low and high perceived neighborhood social cohesion
(p=0.95; Figure 4.1a), the difference between persons eligible and not eligible for treatment (p<0.01;
Figure 4.1b), and the lack of difference between residents of high- or very-high-poverty vs. low- or
medium-poverty neighborhoods (p=0.46; Figure 4.1c).
The Spearman correlation coefficient between perceived neighborhood social cohesion and
neighborhood-level poverty was 0.24 (analysis not shown in tables), indicating a low correlation, and thus,
suggesting that they capture independent constructs.
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Unadjusted and adjusted models
Table 4.2 presents the unadjusted and adjusted HRs for HIV viral suppression among CSBS
participants newly diagnosed with HIV in NYC. The unadjusted HRs show that perceived neighborhood
social cohesion was not associated with suppression. Persons who were black or Hispanic, born in the
US or a US dependency, diagnosed in 2006-2009, or not eligible for treatment were at least 42% less
likely to achieve viral suppression (range 42% to 60%) than others.
Multivariable regression included perceived neighborhood social cohesion, age at HIV diagnosis,
sex at birth, race/ethnicity, year of HIV diagnosis, ART eligibility, and neighborhood-level poverty.
Perceived neighborhood social cohesion was not associated with suppression in the fully adjusted model,
nor were year of diagnosis or neighborhood-level poverty, which were among the potential confounders
included. The likelihood of viral suppression was 55% lower for blacks or Hispanics (95%CI=0.23-0.86)
than persons of another race/ethnicity, and 42% lower among persons not eligible for treatment
(95%CI=0.35-0.96) than treatment-eligible persons, after adjustment. Compared with a model with
variables for age at HIV diagnosis, sex at birth, race/ethnicity, year of HIV diagnosis, treatment eligibility,
and neighborhood-level poverty, this model which added cohesion did not have significantly better fit (2LL: 618.149; p=0.3372; see Appendix 10).
It is worth noting that these adjusted results for social cohesion remained similar when using a
three-level rather than dichotomous variable (see Appendix 8).

Discussion
Controlling for individual characteristics and neighborhood poverty, perceived neighborhood
social cohesion did not influence the time from HIV diagnosis to viral suppression. However, persons
who were black or Hispanic and who were not eligible for treatment were less likely to achieve HIV viral
suppression after diagnosis.
Our findings were not consistent with previous studies that have found a relationship between
perceived neighborhood social cohesion and care-seeking behavior or STI outcomes.[44-46] Our study
may have been underpowered to detect an effect of cohesion on suppression. However, it is also
possible that cohesion is not associated with condom use, STIs, and care-seeking behaviors among
persons with HIV in NYC, or that other factors may prevent social cohesion from influencing time to
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suppression. For example, the system of care and services, benefits, and large HIV-positive population
in NYC make it a relatively attractive place for HIV-positive persons to live and receive care. These
factors may affect the time to suppression regardless of neighborhood cohesion.
Findings about race/ethnicity and treatment eligibility were consistent with a previous study using
NYC HIV surveillance data.[15] Treatment eligibility and suppression were associated with each other
presumably because treatment-eligible persons were more likely to have been prescribed ART, almost
the exclusive means of lowering viral load. However, our findings on poverty were not consistent with
previous studies; neighborhood-level socioeconomic factors have been associated with HIV diagnosis
rates and some care-related outcomes in NYC and elsewhere.[31, 33, 38-42] Possible explanations for
this inconsistency include: different outcomes (e.g., time from ART initiation to suppression vs. time from
diagnosis to suppression); different settings (e.g., Canada vs. US, or other US areas vs. NYC); HIV care
is perhaps comparably accessible and effective regardless of characteristics of the NYC neighborhood in
which people live, mitigating neighborhood-level disadvantage after diagnosis; and publication bias may
have limited the publication of previous null findings on neighborhood characteristics and HIV
outcomes.[82, 83]
Limitations
As in any population-based analysis of HIV care, ours had VL data only when persons sought
care, which was at their discretion. Persons in this analysis were not necessarily tested at regular
intervals. Persons may have achieved suppression sometime before it was measured in a VL test. It is
not clear whether these circumstances would have biased our hazard ratios. However, all persons in the
analysis had at least one VL test between 8 days post-diagnosis and censoring. Persons diagnosed in
2009, for example, had a median of 13 VL tests (IQR: 7-17), and the median interval between tests was
140 days (<5 months; IQR: 106-264 days). Persons diagnosed in 2012 had a median of 8 tests (IQR: 610) and the median interval between tests was 85 days (<3 months; IQR: 67-98 days). These statistics
indicate that the majority of New Yorkers recently diagnosed with HIV and interviewed by CSBS were
engaged in care at intervals that were both consistent with federal guidelines and sufficiently frequent to
produce estimates of suppression. Thus, it is unlikely that the lack of regular testing would have
influenced our results.
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Persons in this analysis were interviewed by CSBS, numbered fewer than 100 (n=92), and nearly
universally achieved suppression by the end of the follow-up period. That these persons could be found
in NYC and were sufficiently available for an interview suggests that they may differ from other recently
diagnosed and reported New Yorkers, i.e., they may be more likely to still be living in NYC, be in care,
and achieve suppression, although it is unclear whether this might affect the relationship between
cohesion and suppression. Similarly, analyses of persons with HIV in NYC (who were not necessarily
recently diagnosed, unlike our analysis population) found that many reported to surveillance appeared to
no longer live in NYC, and when those were excluded, the rates of care were higher.[14]
This analysis was conducted with a small population considering the numerous factors we sought
to control for in multivariable analysis, and the study may have been underpowered. A post-hoc power
calculation found that this study had only a 17% chance of rejecting the null hypothesis (i.e., no difference
in suppression by perceived neighborhood social cohesion level).[107] It may also be that persons
certainly in NYC (in this analysis, indicated by having been interviewed by CSBS) have high rates of
suppression and that differences by subgroups are relatively small, offering an alternative explanation of
why only a few characteristics were significantly associated with suppression. A previous study of newly
diagnosed persons who, according to surveillance records, appeared never to have entered HIV care
found that three times as many of these persons reported that they were in fact in care as the number
who agreed that they were out of care.[108] With near-universal care engagement among persons
completing CSBS interviews, subgroup differences in suppression may indeed be minor, supporting our
findings that few factors measured by surveillance or the CSBS interview instrument were associated with
suppression.
There are several steps between diagnosis and suppression in the continuum of care for HIVpositive persons.[10, 13] By design, this analysis did not elucidate the exact step(s) at which the factors
measured affect suppression. This means that the associations that we found exist for the overall
process from diagnosis to suppression but not necessarily for individual steps between them. For
example, cohesion may not influence time from diagnosis to linkage of care but rather only time from
linkage to suppression.
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Strengths
This is the first analysis to investigate the influence of perceived neighborhood social cohesion on
HIV outcomes, and among the first US analyses to use surveillance data to investigate the role of
neighborhood factors on HIV outcomes. [31, 33, 35, 45, 46, 87] The data were drawn from the
population-based HIV surveillance system of the city with largest HIV epidemic in the US, including only
persons confirmed (by locating them at an NYC address) to still be in the jurisdiction. Data from multiple
sources were used to assess the potential influence on viral suppression of factors beyond the individual.
Mandatory electronic reporting of laboratory tests in NYC provided information about all measured VLs for
all HIV-positive persons receiving care in NYC, as opposed to in a clinical trials environment, where
findings can differ from those in a population setting.
Conclusions
New Yorkers recently diagnosed with HIV, confirmed to be in NYC, and available for interview
have almost universally achieved viral suppression. Being non-black or non-Hispanic and eligible for
ART was associated with faster viral suppression after diagnosis, presumably leading to improved health
and preventing ongoing HIV transmission. In contrast, individuals with characteristics associated with
slower achievement of suppression may need more assistance after diagnosis with linkage to and
retention in care or acquiring and adhering to ART. For example, black and Hispanic persons may
benefit from more-frequent medical care and prescription of ART, including equitable prescribing behavior
and/or better adherence support.[92] These changes may have the potential to raise suppression rates
among blacks and Hispanics to levels that are comparable to those among whites.[15, 22, 25-27, 91]
The racial/ethnic disparity in viral suppression was not related to estimated poverty status nor
neighborhood poverty. Since 2010, New York State law has required all providers to link positive patients
to care, and the United States Department of Health and Human Services now encourages antiretroviral
therapy for all diagnosed persons, regardless of CD4 count, which should further the improvement in
suppression rates. Future studies should explore the extent to which persons who can be located for a
CSBS interview are representative of persons with HIV in NYC.
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Table 4.1. Achievement of HIV viral suppression among a stratified random sample of persons newly diagnosed with HIV
in New York City in 2006-2012 who were interviewed and followed through June 2014

Total
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Total
Perceived neighborhood social
cohesion
Low cohesion
High cohesion
Age group (years) at diagnosis
13 - 29
≥30
Sex at birth
Male
Female
Race/Ethnicity
Black or Hispanic
Another race/ethnicity
Country of birth
US or US dependency
Foreign
HIV transmission risk
Men who have sex with men
Heterosexual

Distribution (n)
100.0 (92)

Not
virologically
suppressed
within 12
months

Distribution (n)
100.0 (32)

Virologically suppressed within 12
months

Distribution (n)
100.0 (60)

Prevalence
65.2

pvalue1

Median time from
diagnosis to
suppression
Median
(IQR2)
days
180 (307)

0.0194

0.3126
52.2 (48)
47.8 (44)

59.4 (19)
40.6 (13)

48.3 (29)
51.7 (31)

60.4
70.5

204 (435)
168 (234)
0.0017

0.0040
33.7 (31)
66.3 (61)

53.1 (17)
46.9 (15)

23.3 (14)
76.7 (46)

45.2
75.4

377 (600)
164 (138)
1.0000

0.8810
72.8 (67)
27.2 (25)

71.9 (23)
28.1 (9)

73.3 (44)
26.7 (16)

65.7
64.0

180 (366)
189 (323)
0.0060

0.0085
82.6 (76)
17.4 (16)

96.9 (31)
3.1 (1)

75.0 (45)
25.0 (15)

59.2
93.8

68.5 (63)
31.5 (29)

84.4 (27)
15.6 (5)

60.0 (36)
40.0 (24)

57.1
82.8

203 (390)
136 (99)
0.0003

0.0165
218 (428)
135 (84)

0.5434

0.2998
51.1 (47)
31.5 (29)

53.1 (17)
37.5 (12)

50.0 (30)
28.3 (17)

63.8
58.6

pvalue3

186 (293)
210 (352)

Other or unknown
Year of HIV diagnosis
2006 – 2009
2010 – 2012
Eligible for treatment
Yes
No
Estimated poverty status
Non-poor
Poor
Percent of population below
federal poverty threshold in
past 12 months

17.4 (16)

Low or medium (<20%)
High or very high (≥20%)

42.4 (39)
57.6 (53)

9.4 (3)

21.7 (13)

81.3

168 (105)
0.2015

0.0536
45.7 (42)
54.3 (50)

59.4 (19)
40.6 (13)

38.3 (23)
61.7 (37)

54.8
74.0

200 (768)
171 (203)
<0.0001

46.7 (43)
53.3 (49)

18.8 (6)
81.3 (26)

61.7 (37)
38.3 (23)

86.0
46.9

39.1 (36)
60.9 (56)

43.8 (14)
56.3 (18)

36.7 (22)
63.3 (38)

61.1
67.9

0.0057
159 (119)
372 (735)
0.1915

0.5073
201 (297)
173 (320)

0.0869
0.2558
34.4 (11)
65.6 (21)

46.7 (28)
53.3 (32)

71.8
60.4

171 (312)
199 (308)
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1

p-value: Chi-square or (when cells had expected counts <5) Fisher's exact test of association between each variable and achievement of suppression

2

IQR: Interquartile range, i.e., 3rd quartile minus 1st quartile

3

p-value: Mann-Whitney U test of differences by each variable in median days to suppression

Table 4.2. Proportional hazards regressions of HIV viral suppression
among a stratified random sample of persons newly diagnosed with
HIV in New York City in 2006-2012 who were interviewed and
followed through June 2014

Perceived neighborhood social
cohesion
Low cohesion
High cohesion
Age group (years) at diagnosis
13 - 29
≥30
Sex at birth
Male
Female
Race/Ethnicity
Black or Hispanic
Another race/ethnicity
Country of birth
US or US dependency
Foreign
HIV transmission risk
Men who have sex with men
Heterosexual
Other or unknown
Year of HIV diagnosis
2009 - 2009
2010 - 2012
Eligible for treatment
Yes
No
Estimated poverty status
Non-poor
Poor

HR1
(95% CI)

AHR2
(95% CI)

1.00
0.99 (0.64-1.51)

1.00
0.79 (0.49-1.28)

0.69 (0.44-1.08)
1.00

0.64 (0.38-1.09)
1.00

0.93 (0.58-1.50)
1.00

0.95 (0.57-1.60)
1.00

0.40 (0.23-0.69)
1.00

0.45 (0.23-0.86)
1.00

0.48 (0.30-0.77)
1.00
0.94 (0.58-1.50)
1.00
1.19 (0.63-2.24)
0.58 (0.37-0.91)
1.00

0.63 (0.38-1.05)
1.00

1.00
0.45 (0.29-0.70)

1.00
0.58 (0.35-0.96)

0.80 (0.52-1.24)
1.00

Percent of population below
federal poverty threshold in
past 12 months
Low or medium (<20%)
High or very high (≥20%)

1.00
0.61 (0.28-1.34)

1

HR: Hazard ratio; CI: confidence interval

2

AHR: Adjusted hazard ratio
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1.00
1.00 (0.98-1.02)

Figure 4.1. Kaplan-Meier survival curves of time from HIV diagnosis to viral suppression
among a stratified random sample of persons newly diagnosed with HIV in New York City
in 2006-2012 who were interviewed and followed through June 2014

Figure 4.1a. By perceived neighborhood social cohesion (p=0.95)

Survival function: Achievement of first HIV
viral suppression after diagnosis
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Figure 4.1b. By eligibility for antiretroviral therapy (ART) at diagnosis (p<0.01)

Survival function: Achievement of first HIV
viral suppression after diagnosis
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Figure 4.1c. By neighborhood-level poverty (p=0.46)
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Chapter 5. Discussion
Overview
We measured the association of individual, facility, and neighborhood characteristics with the
achievement and maintenance of HIV viral suppression among NYC residents diagnosed with HIV
between 2006 and 2012. The dates of HIV diagnosis, viral suppression, and virologic failure were
assessed using the NYC HIV surveillance registry, which included all persons diagnosed or receiving
care in NYC as well as electronic reports of all of their subsequent viral load tests in NYC. Facility-level
characteristics were obtained from the registry and based on facility of diagnosis or of first suppression.
Finally, neighborhood-level characteristics were acquired from the US Census and American Community
Survey based on Census tract or ZIP code of residence. The association of perceived neighborhood
social cohesion with suppression was assessed for recently diagnosed New Yorkers interviewed by
CSBS. For each analysis, the distribution of characteristics in the analytic population, the proportion
achieving the outcome of interest within 12 months, and the median time to the outcome were presented.
Kaplan-Meier curves were generated and log-rank tests performed to test for differences between
subgroups in the likelihood of suppression. Then multivariable proportional hazards regressions were
fitted to assess the likelihood of suppression or failure by individual, facility, and neighborhood
characteristics, accounting for clustering of outcomes by facility or neighborhood whenever the sample
size allowed it. Main findings and interpretations are reviewed in the following section.

Summary of findings
Chapter 2
This chapter assessed the association of individual, facility, and neighborhood factors associated
with achievement of viral suppression after diagnosis among New Yorkers newly diagnosed with HIV in
2006-2010 (Aim 1). Of 12,547 New Yorkers newly diagnosed with HIV in 2006–2010, approximately
three-quarters were 20-49 years old (78.7%), male (74.2%), and black or Hispanic (81.5%); and almost
one-third were eligible to receive treatment based on CD4 and diagnosis year (30.6%). Forty-four
percent of the population achieved suppression within 12 months of diagnosis, with a median time to
suppression of 245 days. Suppression was achieved most slowly among persons who were younger,
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diagnosed in earlier years, not known to be eligible for treatment, and diagnosed at non-hospital facilities
and facilities farther from the patient’s residence.
In proportional hazards models adjusting for individual and facility or neighborhood
characteristics, we observed that persons 13-49 years old, men, blacks and Hispanics, US-born,
heterosexuals, persons diagnosed in 2006 and 2008 were less likely to achieve suppression than those
60 and older, women, whites, foreign-born, MSM, and persons diagnosed in 2010, respectively. This was
also observed for persons not eligible for treatment vs. treatment-eligible persons, and persons
diagnosed at facilities that diagnosed 10-74 patients per year vs. facilities that diagnosed ≥75 patients
per year, that were screening/diagnosis/referral sites vs. hospitals, or that were <1 mile from the patient
vs. 1 to <5 miles. Neighborhood-level poverty, unemployment, and percent black residents were not
associated with suppression.
Chapter 3
This chapter used the subset of persons from the previous aim’s analytical sample who achieved
viral suppression to assess the individual, facility, and neighborhood factors associated with maintenance
of viral suppression (Aim 2). Of 8,927 New Yorkers newly diagnosed with HIV in 2006–2010 who
achieved viral suppression, almost one-fifth (18.2%) experienced failure within 12 months of suppression
with an overall median time to failure of 728 days, i.e., about two years after first suppression.
Adjusting for individual and facility or neighborhood characteristics, proportional hazards models
show the following groups to be the least likely to maintain suppression: younger persons (<50 years old
vs. ≥60), blacks and Hispanics, US- and US-dependency born persons, heterosexuals and injection drug
users, persons with CD4 counts ≥500 cells/mL at suppression, persons receiving care at facilities that
were not large outpatient facilities or large private practices, and residents of high- or very-high-poverty
neighborhoods.
Chapter 4
This chapter assessed individual and neighborhood factors, particularly perceived neighborhood
social cohesion, associated with achievement of viral suppression after diagnosis, among a sample of
New Yorkers newly diagnosed with HIV in 2006-2012 (Aim 3). Out of 92 New Yorkers newly diagnosed
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with HIV in 2006–2012 and interviewed by CSBS, 65% achieved suppression within 12 months of
diagnosis. Almost the entire population (95.7%) achieved viral suppression by the end of the follow-up
period on June 30, 2014, with a median of 180 days. Kaplan-Meier curves indicated no difference in time
to suppression by perceived neighborhood social cohesion. In regression adjusting for age at HIV
diagnosis, sex at birth, race/ethnicity, year of HIV diagnosis, ART eligibility, and neighborhood poverty,
perceived neighborhood social cohesion was not associated with suppression.

Limitations
As in any population-based analyses of HIV care, ours had VL data only when persons sought
care, which was at their discretion. Persons in our analyses were not necessarily tested at regular
intervals. Thus, they may have achieved suppression or failure sometime before it was measured in a VL
test. It is not clear whether these circumstances would have biased our hazard ratios. However, the
majority of New Yorkers newly diagnosed with HIV between 2006 and 2012 were in fact engaged in care
as frequently as was recommended by federal guidelines.
Persons not receiving care in NYC were presumed to be present and unsuppressed (in the
analyses of time to suppression) or maintaining suppression for 12 months (in the analysis of time to
failure), although they may have moved out of NYC and become suppressed or experienced failure
elsewhere. Non-ascertainment of outmigration is a typical limitation of local HIV surveillance data and
may be differential across subgroups. For example, if outmigration happened more frequently among
men, which has been reported previously,[85] this could exacerbate the male-female disparity in
suppression rates.
For the Aim 3 analysis, the analytical sample was fewer than 100 and with higher suppression
rates than newly diagnosed persons citywide. We were underpowered to detect a difference in
suppression between persons perceiving low vs. high neighborhood social cohesion. That these persons
could be found and interviewed suggests that they may have higher rates of care than other newly
diagnosed New Yorkers.[14] However, they may not necessarily have different predictors of suppression
otherwise. A previous analysis of all NYC residents newly diagnosed with HIV found younger age and
earlier year of diagnosis to be associated with delayed suppression.[15, 109] Alternatively, it may be that
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persons certainly in NYC (such as CSBS participants) have high rates of suppression and that differences
between subgroups are relatively small.
There are several steps between diagnosis and suppression in the “care continuum” for HIVpositive persons.[10, 13] By design, our analyses did not elucidate the exact step(s) of the continuum –
diagnosis, linkage to care, retention in care, provision of ART, or viral suppression – at which the
characteristics studied affect suppression.

Strengths and public health significance
These are among the first analyses in the US to investigate the influence of facility and
neighborhood, and the first to assess the influence of perceived neighborhood cohesion, on HIV
outcomes using surveillance data,[31, 33, 35, 45, 46, 87] The data were drawn from population
surveillance in a diverse city with the largest HIV epidemic in the US. Analyses combined data from
multiple sources to assess the potential influence on the achievement and maintenance of viral
suppression of factors beyond the individual. Mandatory electronic reporting of laboratory tests in NYC
provided information about all measured VLs for all HIV-positive persons receiving care in NYC, as
opposed to in a clinical trials environment, where findings can differ from those in a population setting.
This makes our results generalizable to the population of NYC residents with HIV. To assign area-based
characteristics to individuals, we used, whenever available, patient address geocoded to the Census
tract, which is the gold standard for detection of public health disparities.[47] Aim 3 data included only
persons confirmed (by locating them at an NYC address) to still be in the jurisdiction. This ensures that
factors found to be associated with suppression are truly that, and not simply proxies for continued
residence in NYC.

Policy recommendations and future research directions
We have identified individual, facility, and neighborhood characteristics that seem to help persons
newly diagnosed with HIV to achieve and maintain viral suppression, and thus, improve their health and
prevent ongoing HIV transmission. These individuals, health care facilities, or neighborhoods with
characteristics associated with slower achievement of suppression may need more assistance with postdiagnosis linkage to and retention in care, ART prescribing, or adherence. Such supports might include
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care coordination, case management, behavioral counseling, strategic planning about the locations of
facilities, or additional training for physicians. Below we describe the implications of our findings in each
of these arenas in more detail as well as revisit the issue of study design and interviews of persons with
HIV. Our findings may be valuable to agencies planning testing programs, medical care for individuals
with HIV, and “prevention with positives” programs. The agencies may wish to evaluate their effectiveness
with these populations and/or expand their scope to reach most-affected groups or neighborhoods. Our
findings may also help strengthen existing programs that appear to be working, such as the NYC care
coordination program and housing services,[66, 67] or help explain why others may not work. For
example, they may wish to place additional focus on individuals, facilities, or neighborhoods with
characteristics associated with poorer achievement or maintenance of suppression; or review programs
that help patients achieve relatively high rates of good outcomes in spite of challenges (i.e., serving
persons who typically have poorer outcomes), as potential examples of best practices.
Individual characteristics
Several individual characteristics had previously been found to be associated with the
achievement and maintenance of suppression,[15, 20, 21] and our adjusted analyses confirmed these
associations. For example, persons who were older, white, foreign-born, diagnosed in later years, MSM,
and eligible for ART were more likely to achieve and maintain suppression. Changing treatment
guidelines favoring universal consideration of ART initiation will likely minimize the association of CD4
count (and somewhat, by extension, age) with suppression, but disparities by stage of illness and other
factors, such as demographics, may remain. For example, black persons need better HIV-related care
and/or support that permits them to receive optimal ART regimens and achieve and maintain suppression
at comparable rates as whites;[15, 22, 25-27, 91] rectifying this disparity, which Chapter 4 suggested was
related to individual race/ethnicity and not individual poverty status, neighborhood poverty, or
neighborhood racial composition, may require more equitable prescribing behavior and/or better
adherence support.[92]
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Health care facility characteristics
We found a few associations between distance from a person’s residence to their health care
facility and achievement and maintenance of suppression. The extensiveness of NYC’s systems of HIV
care and public transportation,[97] coupled with New York State’s generous benefits and services for
persons with HIV,[98] may have helped minimize the impact of patient-provider distance on virologic
suppression failure.
NYC can continue to encourage HIV testing at large facilities, including hospitals, where patients
have the greatest likelihood of reaching suppression quickly. We can also increase the technical capacity
of certain types of facilities, namely those that make fewer diagnoses annually, or that are neither
hospitals nor private physicians’ offices. These types of facilities need to do a better job at moving their
patients along the continuum of care from diagnosis to suppression. An alternative solution may be
ensuring effective linkage to care at a different type of site, such as one that has cared for more HIVpositive patients. Health care facilities where patients have better achievement and maintenance of
suppression could be examined for their “best practices” and these practices considered either for scaleup across facilities or as recommendations of which types of facilities have the potential to provide the
best care.
Several developments are encouraging all New Yorkers diagnosed with HIV to move along the
continuum of care. Since 2010, New York State law has required all providers to link HIV-positive
patients to care.[110] The United States Department of Health and Human Services now encourages
antiretroviral therapy for all diagnosed persons, regardless of CD4 count.[3] Both sets of guidelines
should further the improvement in suppression rates. Future studies should monitor whether facility-level
disparities in suppression decrease over time, as more facilities presumably adhere to the law.
Neighborhood characteristics
We found that neighborhood-level poverty influences maintenance of suppression but not
achievement of suppression. This suggests that the many resources available for low-income PLWHA in
NYC to receive care, medication, and other forms of support may reduce but not entirely eliminate the
negative effects of poverty on HIV-related health outcomes. It is possible that the effects of
neighborhood-level poverty would have been even larger in a setting other than NYC that may not have
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been as well-resourced vis-à-vis medical facilities and transportation system. Still, rectifying the disparity
in maintenance of suppression between residents of poorer and wealthier neighborhoods may require
targeted adherence support services or additional general poverty alleviation, including increased units of
subsidized and/or supportive housing.
Study design
We found near-universal care engagement and viral suppression among persons completing
CSBS interviews, while figures among newly diagnosed PLWH overall were more modest. Future studies
should explore the extent to which persons who can be located for an interview are representative of
persons with HIV in NYC.

Conclusions
Our analyses are among the first in the US to reveal facility and neighborhood characteristics
associated with achievement and maintenance of viral suppression among persons newly diagnosed with
HIV. We confirm that several individual characteristics appear to also influence suppression, but
perceived neighborhood social cohesion may not. We rely on population surveillance and interviews of
persons sampled from surveillance, and matched both with US Census Bureau data to obtain information
on neighborhood-level characteristics. Our results from Aims 1 and 2 are generalizable to the population
of persons living with HIV in NYC, and further exploration of the representativeness of persons with HIV
who can be located for an interview would be valuable. Increases in post-diagnosis linkage to and
retention in care, and receipt of and adherence to ART, that reach groups of persons, patients at facilities,
or residents of neighborhoods that we found to have poorer outcomes, may improve the achievement and
maintenance of viral suppression in NYC.
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Appendix 1. Populations for analyses of achievement (Aim 1) and maintenance
(Aim 2) of HIV viral suppression among newly diagnosed New Yorkers

20,285 persons diagnosed 2006-2010, per latest registry dataset
20,225 persons 13+ years old at diagnosis, per latest registry dataset
17,825 NYC residents, per latest registry dataset
15,265 had XY coordinates of address of residence at diagnosis and were geocoded to census tract
based on XY coordinates
15,084 had non-missing census tract-level variables
15,059 had non-missing facility of diagnosis
14,588 had non-zero distance from residence at diagnosis to facility of diagnosis
(eliminate homeless and some institutionalized persons, whose residence is set to facility address)
14,336 were not diagnosed at a correctional facility
14,116 had no death date or it occurred at least 31 days after diagnosis
(eliminate persons with pre-diagnosis death or death in first month)
13,400 had a Western blot (confirmatory test) within 31 days post-diagnosis or were an acute HIV
infection
(eliminate persons likely to have misclassified diagnosis date)
13,399 did not have a detectable (>50 copies/mL) viral load >31 days prior to diagnosis or were an acute
HIV infection
(eliminate persons likely to have misclassified diagnosis date)
Population
for Aim 1

12,547 did not have a suppressed (≤400 copies/mL) viral load ≤31 days after diagnosis
(eliminate persons likely to have misclassified diagnosis date)
9,459 ever achieved viral suppression ≥31 days after diagnosis
9,135 achieved suppression by end of follow-up (12/31/2012)
9,132 had no death date or it occurred after suppression
(eliminate persons with pre-suppression death)
9,125 had non-missing facility of suppression

8,993 had non-zero distance from residence at diagnosis to facility of suppression
(eliminate homeless and some institutionalized persons, whose residence is set to facility address)
Population
for Aim 2

8,927 were not suppressed at a correctional or screening/diagnostic facility
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Appendix 2. Population for analysis of HIV viral suppression among recently
diagnosed and interviewed New Yorkers (Aim 3)
298 persons sampled from HIV surveillance registry for Case Surveillance-Based Sampling project
294 unique persons after removal of duplicates
142 persons diagnosed in 2006-2012 and 13+ years old at diagnosis, per latest registry dataset
134 NYC residents, per latest registry dataset
133 have ZIP code of address of residence at diagnosis
133 had non-missing ZIP-level variables from ACS/Census
133 had no death date or it occurred at least 31 days after diagnosis
(eliminate persons with pre-diagnosis death or death in first month)
127 had a Western blot (confirmatory test) within 31 days post-diagnosis or were an acute HIV infection
(eliminate persons likely to have misclassified diagnosis date; was 5% loss at this step for Aim 1)
127 did not have a detectable (>50 copies/mL) viral load >31 days prior to diagnosis or were an acute
HIV infection
(eliminate persons likely to have misclassified diagnosis date)
116 did not have a suppressed (≤400 copies/mL) viral load ≤31 days after diagnosis
(eliminate persons likely to have misclassified diagnosis date)
Population
for Aim 3

92 had responses to all three questions about perceived neighborhood social cohesion
88 ever achieved viral suppression ≥31 days after diagnosis
88 achieved suppression by end of follow-up (6/30/2014)
(FYI: 60 of them achieved suppression within 12 months)
88 had no death date or it occurred after suppression
(eliminate persons with pre-suppression death)
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Appendix 3. Creating a dataset of individual, neighborhood, and facility
characteristics, January – May 2014
January 16 and 17, 2014 – Preparing individual-level dataset; reading in area-level variables
SAS
Added correctional variables, individual-level variables, first VL, first CD4, and provider XY coordinates.
They are in a single completed SAS program and saved in a permanent SAS dataset called
IndivSurvDataForGCCases_20140117. “GCCases” refers to geocoded cases.
Began a SAS program to read in and combine area-level datasets. Read in all ACS datasets and need to
refer to Excel list at home of neighborhood-level variables, since some ACS datasets have hundreds of
variables and the Excel list identifies the exact variable needed. Not all datasets have the same format
for the geographic variables describing CT, so those will need to be made into the same format before
merging.
Outcome
Finalized dataset with individual-level variables. Need to continue reading in and combining area-level
variables. Have patient and provider XY coordinates and at some point need to do network analysis to
calculate distance between them.
January 21, 2014 – Compiling area-level variables
SAS
Continued SAS program to read in and combine area-level datasets. Read in all needed CT-level ACS
and Census data. Compared poverty datasets from ACS downloads done by borough and for NYC
overall, and CT-level poverty stats between the two appeared to be a perfect match, which was
reassuring. Converted all percentages into the same format (e.g., xx.x), since some were formatted as
xx.x%, and formatted geographic info the same across datasets (as GEO_display_label in ACS was
formatted) so they can be merged. Apparently there are 2,168 Census tracts in NYC with population
data; this is the number of observations in the final area-level dataset.
January 23, 2014 – Creating permanent dataset of area-level variables
SAS
Finished program for CT-level data and saved permanent copy.
BES/DTF slides from approx. 1/16/2014 on combined/split CTs and ZIPs suggest that one ZIP perhaps
should be combined with another.
January 28-30, 2014 – Creating facility-level variables, adding Aim 2 maintenance/failure variables,
combining datasets across levels
SAS
Wrote code to determine number of cases diagnosed per provider per year (hars_name, hivdxdtafter year
in harsoct13sm dataset for 2005-2010), number of unique patients seen per provider per year
(hars_name, eventdate year of CD4/VL in vlcd4wbprovoct13 dataset for 2005-2010), and facility type
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(provider and providercode in pv_provider dataset as of 1/30/2014, and DACs per NYS and NYC lists
from 1/2006 – 2013). Saved datasets.
Revisited SAS program for individual-level data to add variables for Aim 2, e.g., 1st CD4 within 1 month
before or after 1st suppressed VL, provider at 1st suppressed VL, and maintenance of suppression (i.e.,
failure per VL >400 or >1,000 or >366 days without a test).
Began SAS code to combine individual, neighborhood, and facility-level datasets.
January 31 and February 3-4, 2014 – Completing dataset for Aims 1 and 2, ruling out possibility of
patient-provider XY distance network analysis
SAS
Checked the completeness of care patient load (FirstSuppVLProv by year of FirstSuppVLDate) and many
were missing. Realized that the care patient load count by provider was only through 2010, so I reran
that through the latest year of care data (2013) and recombined facility-level data with the individual-level
dataset.
Reviewed provider XY coordinate availability and discovered that about one-third of patients that we’d
want to have it (they were diagnosed in 2006-2010 and have a non-missing diagnosing provider) did not
have provider XY coordinates. Looked at frequency of diagnosing providers (hars_name) with missing
XY and found that numerous major providers had not been geocoded to XY coordinates. Network
analysis does not seem possible without a major geocoding effort for providers.
Added dthdate (patient death date) to list of variables pulled from registry dataset, in order to calculate
censor date.
Calculated censor dates, time from diagnosis or suppression to censoring, and whether censoring was
due to the outcome of interest (suppression for Aim 1, failure for Aim 2). Censoring variables for Aim 2
are available at VL>400 and VL>1,000.
Completed SAS code to combine individual, neighborhood, and facility-level datasets.
February 5, 2014 – Reviewing variables and population, and adding hboro
SAS
Read in combined indiv/neighb/facility dataset and reviewed most variables with freqs and measures of
central tendency. All (individual and neighborhood) look okay so far – need to check provider and
outcome variables still.
Added hboro to datasets, to be able to specify the population as persons living in NYC at diagnosed.
April 15, 2014 – Expanding provider characteristics
SAS
Created SAS program to calculate two measures of patient volume: annual diagnoses by provider (for
use in aim 1 for facility of diagnosis) and unique patients cared for by provider (for use in aim 2 for facility
of first viral suppression), as well as facility type (for aims 1 and 2).
April 17, 2014 – Revising neighborhood variables
86

SAS
Created additional variable of percent of population that did not graduate from high school for greater
consistency with the literature. Previously we had variables for percent finishing high school and percent
finishing college. Percent not graduating from high school was calculated as 100 - percent graduating
from high school.
Also divided all neighborhood variables by 10 so that, when modelled as continuous variables, the
resulting measure of association would represent the hazard ratio for each 10-percentage-point increase
in the variable. For example, the percent not graduating high school was 60, but the percent not
graduating high school divided by 10 was 6, and the latter variable was modelled, so the hazard ratio for
each 1-point change in the latter variable represented a 10-percentage-point change.
May 20, 2014 – Excluding persons with possibly misclassified diagnosis date
SAS
Several edits were made between February 5 and May 21 but not documented here, including the
reincorporation of provider XY data since many more had it after a March/April geocoding by Keyi Xu.
On May 20, three exclusions were added to bring the population closely in line with that in Lucia Torian
and Qiang Xia’s paper on viral suppression among newly diagnosed New Yorkers, which sought to
remove persons whose diagnosis dates may have been misclassified. These three exclusions were:
1. Persons who did not have a Western blot within 31 days of diagnosis and were not acute HIV
infections
2. Persons who had a detectable (>50 copies/mL) viral load >31 days prior to HIV diagnosis
3. Persons who had a suppressed (>400 copies/mL) viral load ≤31 days following HIV diagnosis
This resulted in a reduction in our analysis population from 14,065 cases to 12,547 cases. Proportion
suppressed decreased from 73.8 to 72.8% and median time to suppression increased from 225 to 245
days.
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Appendix 4. Calculating shortest distance along NYC streets from patient
residence at diagnosis to facility of diagnosis using Network Analyst in ArcGIS

Created XY datasets. We created a single dataset that included variables for patient identifier (cityno),
XY coordinates for patient residence at HIV diagnosis, and XY coordinates of the facility that diagnosed
HIV in each patient. We transferred this dataset from the most-secure drive to a less-secure drive that
has ArcGIS on it. We split this dataset into two, each with the patient identifier and each one having
either patient or provider XY coordinates. We copied cityno in each XY Excel file into a second column in
each called RouteName. We ensured that patient and provider XY were numeric. We also deleted
provider records with missing XY. We named the files “ptxy20140313” and “provxy20140313.”

Got Network Analyst. We opened ArcMap and in the Customize menu, selected Extensions –
Network Analyst, then closed the window. Then in the Customize menu again, we selected Toolbars –
Network Analyst to get the toolbar for this extension.

Obtained network dataset. We obtained the “MP_Network” network dataset of NYC streets. This
network dataset is a simple network of NYC streets without details that for our purposes would be
extraneous, like which streets are one-way, as we are not interested in actual driving directions. We used
Add Data to add MP_Network and specifically NYC_Streets within it, and said “Yes” to also add to the
map all feature classes that participate in the network dataset. The Network Analyst toolbar now had in
its “Network dataset” window “NYC_Streets_ND.” Three layers showed up from this in the Table of
Contents: lines, dots for junctions, and lines for edges.

Added XY data to map. We clicked Add Data and added ptxy20140313 and provxy20140313 data
from Excel, right-clicked on each to display XY data, and clicked Yes to add the data to the map as a
layer (ptxy Events and provxy Events).

Exported XY data to file geodatabase of network dataset. XY data are most easily routed in
Network Analyst when saved within the file geodatabase of the network dataset. With the ptxy Events
layer, we right clicked, exported data, navigated to the MP_Network geodatabase folder, selected the
geodatabase within that, named ptxy as a personal gdb/features class, closed, clicked Yes to add to map
as layer, and deleted the original Events layer from the Table of Contents. We did the same with the
provxy Events layer. Right-clicked on each to display XY data, and clicked Yes to add to the map as a
layer.

Established settings for routing. In the Network Analyst toolbar, clicked the arrow next to “Network
Analyst” and selected New Route. In the Table of Contents, immediately under the NYC_Streets layer,
we right-clicked on Route  Properties  Analysis settings  Output shape type  Straight line.
Routing as a straight line doesn’t affect the distance being calculated but may help the routing run faster
in ArcMap.

Loaded XY coordinates into Network Analyst. In the Network Analyst window, we right-clicked the
Stops line and (after acknowledging with No that we didn’t want to repair the address locator) clicked
Load Locations, then selected ptxy (the only one with that name in the Table of Contents), selected
sorting by Routename, and checked that the Routename property was affiliated with the Routename field
in our origins (patient) table. We clicked OK, and this ran in about five minutes We right-clicked Stops,
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Load Locations, selected provxy, selected sorting by Routename, and confirmed Routename was
affiliated with Routename field in table, clicked OK, and let ArcMap run for another five minutes.

Calculated and reviewed distances. We clicked the Solve icon (a small square with gridlines and a
blue line) in the Network Analyst toolbar and let it run for 15-30 minutes this time. This calculated the
distances between each person’s residence and facility of diagnosis, as well as created straight-line
“routes” from each patient to his/her facility of diagnosis. We displayed these on the map, added ZIP and
borough shapefiles for context, and exported this map as a PNG image file, not for publication (XY patient
locations are confidential) but for internal visual review. We noted that nearly all of Manhattan was
completely blanketed by routes, and most of the other boroughs were also largely covered.

Saved dataset of distances. In the Network Analyst window, we right-clicked Routes  Data 
Export data  Use the same coordinate system as the data frame  Named it “PtProvDistance” and
saved in the main (non-geodatabase) folder, and said Yes to add exported data to map as a layer. Then
in Windows Explorer, we opened the DBF that was just created that was affiliated with the shapefile, gave
it another name and saved as Excel, kept only cityno and total length (shape length, which was slightly
shorter, is the length of the straight-line route drawn between each patient’s residence and facility of
diagnosis), and created new columns calculating equivalent miles and kilometers from the distance in
feet.

Removed data from less-secure drive. We deleted or transferred back to the most-secure drive all
files on the less-secure drive related to the calculation of patient-provider distance.

I found the following online resources helpful:
ArcGis Network Analyst tutorial at http://help.arcgis.com/en/arcgisdesktop/10.0/pdf/network-analysttutorial.pdf
Post #3 in online forum at http://forums.arcgis.com/threads/30795-calculating-driving-distances

I would like to acknowledge the following persons for their help with network analysis:
Susan Resnick, NYC DOHMH DIIT, for providing network dataset and help with Network Analyst
Andrew Maroko, Lehman College, CUNY, for providing help with Network Analyst, including remotely
walking us through the actual routing
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Appendix 5. Assessing model fit for Aim 1

An Excel table was made indicating the set of variables in each proportional hazards regression model. The -2LL (with covariates) was
recorded from SAS for each model. The difference in -2LL and degrees of freedom were entered into a Χ2 calculator at
https://www.fourmilab.ch/rpkp/experiments/analysis/chiCalc.html on February 4, 2015. We used the “Calculate probability from Χ2 and d” section of
the webpage and manually copied each difference in -2LL, out to three significant digits, into the “Given Χ2=” box, entered each number of
degrees of freedom into the “d=” box, and clicked “Calculate” to get a value in the “The chance probability, Q, is:” box. For example, the model of
time from diagnosis to viral suppression that had all three neighborhood-level variables in addition to the seven individual-level variables had a 2LL of about 158,673, whereas the individual-only model’s -2LL was about 158,675, for a difference of 2.190 with three degrees of freedom (see
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Table A5.1). The calculator indicated that the probability of getting a difference at least as large with these degrees of freedom was 0.5339,
meaning that the addition of the three neighborhood-level variables did not statistically significantly improve the fit of the model over individuallevel variables alone. The model of suppression that had the best fit was that with all individual- and facility-level variables, which had a -2LL of
158,585 (p<0.0001).

Table A5.1. Measures of the fit of proportional hazards models of HIV viral suppression among persons newly diagnosed
with HIV in New York City in 2006-2010 and followed through 2012, by individual, facility, and neighborhood
characteristics
Variable
Age group (years) at
diagnosis
Sex at birth

Variable type

Model 1

Model 2

Model 3

Model 4

Model 5

Model 6

Model 7

Model 8

Model 9

Individual

x

x

x

x

x

x

x

x

x

Individual

x

x

x

x

x

x

x

x

x

Race/Ethnicity

Individual

x

x

x

x

x

x

x

x

x

Country of birth

Individual

x

x

x

x

x

x

x

x

x

HIV transmission risk

Individual

x

x

x

x

x

x

x

x

x

Year of HIV diagnosis

Individual

x

x

x

x

x

x

x

x

x

Eligible for treatment
Number of HIV diagnoses
made annually by health
care facility that
diagnosed patient

Individual

x

x

x

x

x

x

x

x

x

Facility

x

Type of facility that
diagnosed patient

Facility

x

Distance between patient
and provider

Facility

x
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Percent of population
below federal poverty
threshold in past 12
months
Unemployment rate
among population 16
years and over
Percent of population that
is black or African
American only (nonHispanic)
Measure of fit: -2LL ("with
covariates")

x

x
x

Neighborhood

x

Neighborhood

x

Neighborhood

x

x

x

x

158,675

158,585

158,673

158,642

158,626

158,663

158,673

158,675

158,675

Difference in -2LL

N/A

90.080

2.190

33.230

48.860

11.350

2.070

0.040

0.040

Degrees of freedom
p-value

0

3

3

1

1

1

1

1

1

N/A

<0.0001

0.5339

<0.0001

<0.0001

0.0007

0.1502

0.8414

0.8414

Comparison with model
with all individual-level
variables, using Χ2

Appendix 6. Patterns of viral load testing

Of 12,547 persons in our analytic sample for Aim 1, i.e., persons newly diagnosed with HIV in
2006-2010 whose address at diagnosis geocoded to an NYC Census tract, 1,446 (11.52%) had no viral
load (VL) test between 8 days post-diagnosis and their censor date. Thus, 88.5% (n=11,101) of persons
in the analysis had at least one VL test ≥8 days after diagnosis (ranging only narrowly by diagnosis year:
87-90% each year).
Among this group of 11,101 persons, there were a median of 12 (IQR: 7-17) VL tests during
follow-up (median of 17 [IQR: 10-23] among those diagnosed in 2006 and median of 8 [IQR: 5-10] among
those diagnosed in 2010, for whom follow-up time was shorter), with a median interval of 112 (IQR: 90164) days (i.e., 3-4 months) between tests (median of 120 days [IQR: 95-182] among those diagnosed in
2006 and median of 101 [IQR: 84-139] among those diagnosed in 2010). Out of the 11,101 persons with
at least one VL test ≥8 days after diagnosis, 19% had their first VL test within 14 days of diagnosis (i.e., 814 days), 45% within 30 days, 67% within 60 days, 76% within 91 days, 87% within 183 days, 90% within
274 days, and 92% within 365 days.

92

Appendix 7. Young teenagers, facility type and patient volume, changes in
residence over time, and model fit for Aim 2

A7.1. Young teenagers
The discussion argues that information about teenagers is unique because they are rarely
included in analyses of viral suppression before 18 years of age. To support this statement, I checked
the number of persons in the analysis for Aim 2 who were aged 13-17 years at their first viral suppression
after diagnosis. I compared this number with the number of persons 18-19 years old at suppression and
calculated the proportion of persons 13-19 years old (i.e., teenagers, one of the age groups in the
analysis) who were 13-17. I found that 55 of the teenagers were 13-17 years old, and 141 were 18-19
years old (Table A7.1). Thus, 13-17-year-olds comprised a non-negligible number of persons, and 28%
of teenagers, in the analysis. Based on this information, we will keep our argument about teenagers in
the Discussion. As an additional note, only 7 of the 13-17-year-olds were 13-15 years old; 48 were 1617.

Table A7.1. Number of teenagers in analysis, by age group
Age group at first viral suppression

Number of teenagers in
Percentage of teenagers in
analysis
analysis (%)
13-17*
55
28
13-15*
7
4
16-17*
48
24
18-19
141
72
Total teenagers (13-19 years old)
196
100
*These age groups are rarely presented in other analyses of viral suppression.

A7.2. Facility type and patient volume
We found that persons receiving care at facilities with small patient volumes had higher failure
rates than those at facilities with larger patient volumes, and that persons receiving care at facilities that
were not private physicians’ offices had higher failure rates than patients of private physicians, after
controlling for individual and other facility or neighborhood characteristics. To prevent confusion in the
interpretation of these findings, it would be helpful to know if facility type and patient volume were
correlated, e.g., private physicians’ offices had smaller patient volumes. To address this issue, I cross93

tabulated facility type and patient volume among all 8,927 persons in the Aim 2 analysis population and
conducted a Chi-squared test of association. This analysis shows that, for most persons who were first
suppressed at private physicians’ offices (850/1,564, 54%), their facilities saw fewer than 1,000 patients
for HIV-related medical care that year, whereas for most persons who were first suppressed at an
inpatient facility or hospital, their facilities saw at least 1,000 patients (3,865/4,879, 79%; Table A7.2).
The Chi-squared test indicated a statistically significant association between facility type and patient
volume (p<0.0001). However, facility type and patient volume were not equivalent: most persons who
first suppressed at facilities with patient volumes of <250 were not at private physicians’ offices. The
paper was revised so that the proportional hazards models use the combined variable rather than facility
type and patient volume separately.

Table A7.2. Number of persons first suppressed at each facility type, by patient volume
Unique patients
seen for care
(CD4 or VL) at
facility of first
suppression in
year of first
suppression

Facility type
Inpatient /
Hospital
N

Outpatient:
Non-private

Outpatient:
Private

Other /
Unknown

Total

Col. %

N

Col. %

N

Col. %

N

Col. %

N

Col. %

<250

116

2

884

38

850

54

101

54

1,951

22

250 to <1,000

898

18

676

29

608

39

85

46

2,267

25

1,000 to <2,000

2,020

41

216

9

106

7

0

0

2,342

26

>=2,000

1,845

38

522

23

0

0

0

0

2,367

27

4,879

100

2,298

100

1,564

100

186

100

8,927

100

Total

N

Total %

Row %

55

26

18

2

100

A7.3. Changes in residence over time
Residence information from the time of HIV diagnosis was used to provide neighborhood-level
data for persons in the analysis. Address of residence was geocoded to the Census tract, which was
then used to assign neighborhood poverty level, percent black, and percent unemployed. Complete and
accurate geocoding is labor-intensive, so we did not attempt to determine or geocode address at the time
of first suppression. Rather, we assumed that the characteristics of a person’s Census tract of residence
94

at first suppression were the same as those at diagnosis. To better understand how this might affect the
internal validity of our results, we assessed moves among NYC residents 13+ who were diagnosed in
2006-2010 and would go on to achieve suppression ≥31 days after diagnosis and by the end of the
follow-up period (12/31/2012). In the October 2013 analytic dataset, this included 12,584 persons, quite a
bit more than the dissertation Aim 2 analysis population of 8,927. This may be because of the loss in the
dissertation analysis of persons whose address at residence did not geocode, plus other exclusion
criteria, which could not readily be included for this appendix analysis.
Among these 12,584 persons, we compared the United Hospital Fund (UHF) neighborhood,
borough, and ZIP-level poverty level of their residence at diagnosis with their UHF neighborhood,
borough, or ZIP-level poverty level, respectively, as of the end of (a) their diagnosis year and (b) the next
calendar year. For example, for someone diagnosed anytime in 2007, we assessed whether the UHF at
diagnosis was the same as the UHF as of the end of 2007 and the end of 2008, whether the borough at
diagnosis was the same as the borough as of the end of 2007 and the end of 2008, and whether the
poverty level of their ZIP code at diagnosis was the same as that of their ZIP code as of the end of 2007
and the end of 2008. We chose these measures because they were readily available and because 44%
of persons in the main dissertation analysis for Aim 1 achieved viral suppression within 12 months of
diagnosis. The proportion of persons who would have moved by the time they achieved suppression may
be estimated by the midpoint of the proportion of persons who moved by the end of diagnosis year (for
whom median time elapsed would be six months) and the proportion of persons who moved by the end of
the year after diagnosis (for whom median time elapsed would be 18 months). Residence information in
surveillance is updated largely based on laboratory test values; persons achieving suppression by
definition would have had laboratory test values subsequent to diagnosis (although not necessarily within
one calendar year after diagnosis).
We assessed change in residence overall and by diagnosis year. We found no large differences
by diagnosis year in moves across UHFs, boroughs, or poverty levels, so Table A7.3 (below) presents
statistics on changes in residence aggregated across diagnosis years. Overall, 16% of persons had
changed UHFs by the end of their diagnosis year and 27% by the end of the calendar year following their
diagnosis, 7% had changed boroughs by the end of their diagnosis year and 13% by the end of the
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calendar year following their diagnosis, and 12% had changed poverty levels by the end of their diagnosis
year and 21% by the end of the calendar year following their diagnosis. Midpoints were 21% changing
UHF, 10% changing borough, and 16% changing poverty level.
UHFs are larger than Census tracts, suggesting that more than 21% of persons in our analysis
may have changed Census tract of residence between diagnosis and suppression. The cross-borough
figures are more modest, but those and, to a greater extent, the cross-poverty figures suggest that many
persons moved to places substantially different from those they were living in at diagnosis. Similarly, in
the dissertation Aim 2 analysis, many persons may have moved by the time they achieved suppression to
Census tracts with different characteristics, e.g., poverty level, than the Census tracts they were living in
at diagnosis. Additionally, the rate of moving itself (>21%) suggests that the impact of neighborhoods on
the achievement of viral suppression may be difficult to measure, as many persons live in more than one
neighborhood between diagnosis and suppression, albeit sometimes similar neighborhoods. Our
longitudinal analysis, which uses information about residence at one time point only (and moreover, one
that falls before the baseline), is somewhat limited in its ability to assess the role of neighborhood on
participant outcomes.

Table A7.3. Change in residence among New York City (NYC) residents who were newly
diagnosed with HIV in 2006-2010 and achieved viral suppression by the end of 2012

Timing of the change
By end of By end of year
diagnosis year after diagnosis
(%)
(%) Midpoint (%)

Geographic level
Moved to different UHF neighborhood
Moved to different NYC borough
Moved to ZIP code with different poverty level

16

27

21

7

13

10

12

21

16

*For persons diagnosed in 2007-2010 only, because information about residence at the end of 2006 was
not available.

96

A7.4. Model fit for Aim 2
Table A7.4. Measures of the fit of proportional hazards models of HIV virologic failure after suppression among persons
newly diagnosed with HIV in New York City in 2006-2010 and followed through 2012, by individual, facility, and
neighborhood characteristics
Variable
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Age group (years) at
suppression
Sex at birth
Race/Ethnicity
Country of birth
HIV transmission risk
Year of viral suppression
CD4 count
Facility type by patient
volume

Variable type

Model 1

Model 2

Model 3

Model 4

Individual

x

x

x

x

x

x

x

x

Individual
Individual
Individual
Individual
Individual
Individual

x
x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x
x

x
x
x
x
x
x

Facility

x

Distance between person
and provider

Facility

x

Percent of population below
federal poverty threshold in
past 12 months

Neighborhood

x

Unemployment rate among
population 16 years and over

Neighborhood

x

Percent of population that is
black or African American
only (non-Hispanic)

Neighborhood

x

Measure of fit: -2LL ("with
covariates")

64,140

64,069

Model 5 Model 6 Model 7 Model 8

x
x

64,121

x
x
x

64,071

64,136

64,124

64,132

64,137

Comparison with model with
all individual-level variables,
using Χ2
Difference in -2LL
Degrees of freedom
p-value

N/A
0
N/A

70
2
<0.0001

19
3
0.0002

69
1
<0.0001

4
1
0.0439

16
1
0.1502

8
1
0.0045

2
1
0.8414
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Appendix 8. Clarifying and exploring the Aim 3-specific variable of perceived
neighborhood social cohesion

A8.1. How the Aim 3-specific variable of perceived neighborhood social cohesion was
created
Perceived neighborhood social cohesion was calculated based on the degree of participant
agreement with three statements in the Case Surveillance-Based Sampling (CSBS) interview about trust,
closeness, and helpfulness between neighbors. [45, 46] These statements were:
a. I live in a close-knit neighborhood.
b. People in my neighborhood can be trusted
c.

People in my neighborhood are willing to help each other.

Agreement with each statement were collected using a scored 1-4 Likert scale: strongly agree
(1), agree (2), disagree (3), and strongly disagree (4). Scores for the three responses were summed, and
these sums of 3-12 were dichotomized near the median, at a natural break that would place
approximately equivalent numbers of persons in each category.[46] Specifically, the majority of sums
were 6, 9, or 12 (>20% each), and 48% of persons had sums of 3-8 (see Table A8.1). Lower scores
indicated agreement with positive statements about the neighborhood; perceived neighborhood social
cohesion was classified as high for persons with sums of 3-8 (48% of the sample population) and low for
persons with sums of 9-12 (52% of the sample population; see Table A8.2).
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Table A8.1. Sums of responses to three cohesion-related questions in Case SurveillanceBased Sampling interview, among 92 persons in analysis of viral suppression among
newly diagnosed New York City residents
cohesionOrig: Sum of three cohesion variables
cohesionOrig Frequency Percent Cumulative Cumulative
Frequency
Percent
3

2

2.17

2

2.17

5

3

3.26

5

5.43

6

22

23.91

27

29.35

7

8

8.70

35

38.04

8

9

9.78

44

47.83

9

22

23.91

66

71.74

10

3

3.26

69

75.00

11

4

4.35

73

79.35

12

19

20.65

92

100.00

Table A8.2. Dichotomized cohesion measure based on responses to three cohesionrelated questions in Case Surveillance-Based Sampling interview, among 92 persons in
analysis of viral suppression among newly diagnosed New York City residents

LowCohesion: Poor neighborhood social cohesion (cohesionOrig score is high: 9-12)
LowCohesion

Frequency

Percent

Cumulative
Frequency

Cumulative
Percent

0

44

47.83

44

47.83

1

48

52.17

92

100.00

A8.2 Cohesion as a three-level variable
Perceived neighborhood social cohesion could have been categorized in a way that reflected the
distribution of values differently. Because most persons in our sample had cohesion scores of exactly 6,
9, or 12, we constructed an alternative version of the cohesion variable with three levels rather than two.
For this, cohesion was classified as low if the sum of the three cohesion variables was 10-12, medium if
7-9, and high if 3-6. Approximately equal proportions of the sample population were in each group.
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We ran a multivariable proportional hazards regression with this alternative version of the
cohesion variable (see Table A8.3). As with the original version of the variable, we found that increasing
levels of cohesion were associated with reduced hazards of suppression, and that this association was
still not statistically significant.

Table A8.3. Proportional hazards regressions of
HIV viral suppression among a stratified random
sample of persons newly diagnosed with HIV in
New York City in 2006-2012 who were
interviewed and followed through June 2014,
including perceived neighborhood social
cohesion as a three-level variable
AHR1
(95% CI)
Perceived neighborhood social
cohesion
Low cohesion

1.00

Medium cohesion

0.73 (0.42-1.28)

High cohesion

0.69 (0.34-1.43)

Age group (years) at diagnosis
13 - 29
≥30

0.62 (0.35-1.08)
1.00

Sex at birth
Male
Female

0.93 (0.53-1.61)
1.00

Race/Ethnicity
Black or Hispanic
Another race/ethnicity

0.43 (0.21-0.85)
1.00

Year of HIV diagnosis
2009 - 2009

0.60 (0.35-1.03)

2010 - 2012

1.00

Eligible for treatment
Yes
No

1.00
0.60 (0.36-0.99)

Percent of population below
federal poverty threshold in past
12 months
Low or medium (<20%)
High or very high (≥20%)
1

1.00
1.00 (0.98-1.03)

AHR: Adjusted hazard ratio
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Appendix 9. The creation of the Aim 3-specific variable for individual-level
poverty, i.e., estimated poverty status
Aim 3 was limited to persons interviewed by the Case Surveillance-Based Sampling project,
which, unlike routine HIV surveillance in NYC, asked participants’ household size and income. This
provided a unique opportunity to assess poverty at the household/individual level. (Both CSBS and
routine HIV surveillance collect information about the place of residence of New Yorkers with HIV and can
use residence data in combination with US Census Bureau data to assess neighborhood-level poverty.)
In short, we combined US Census statistics on poverty thresholds by family size with self-reported
household income from CSBS and number of persons who depended on the income (which we treated
as a proxy for family size), to create a variable dichotomizing each person as poor or non-poor. We
called this measure “Estimated poverty status,” and this appendix provides more details about its
creation.
The relevant CSBS variables to create this poverty measure are described in the CSBS protocol’s
Appendix D1, “2012/2013 Case-Surveillance-Based-Sampling Questionnaire for The Medical Monitoring
Project (MMP)” (see Figure A9.1). Monthly or yearly income was collected only as a range of values, not
a specific dollar amount.
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Figure A9.1. Questionnaire extract for income-related questions

CSBS participants were asked to use a response card to indicate either their monthly or yearly
income (see Figure A9.2).
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Figure A9.2. Participant response card for monthly and yearly income questions

Variables for monthly and yearly income had corresponding values, such that the lowest category
of monthly income response would be equivalent to the lowest category of yearly income response, were
that monthly income earned for 12 months (see Table A9.1). For example, persons in households
earning up to $4,999 in a year would earn $4,999/12 = $416/month, and either response was coded as a
“1.”
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Table A9.1. Codebook of CSBS participant responses for monthly and yearly income and
number of persons depending on the income
MTH_IN12

8

Monthly combined household
income^[MTH_IN12]

1

(1)a. $0 to $416

2

(2)b. $417 to $833

3

(3)c. $834 to $1249
(4)d. $1250 to
$1666
(5)e. $1667 to
$2499

4
5
6

8

(6)f. $2500 to $3333
(7)g. $3334 to
$4166
(8)h. $4167 to
$6249

9

(9)i. $6250 or more

D

(D)Don't Know

S

Skipped

1

9

(1)j. $0 to $4,999
(2)k. $5,000 to
$9,999
(3)l. $10,000 to
$14,999
(4)m. $15,000 to
$19,999
(5)n. $20,000 to
$29,999
(6)o. $30,000 to
$39,999
(7)p. $40,000 to
$49,999
(8)q. $50,000 to
$74,999
(9)r. $75,000 or
more

D

(D)Don't Know

S

Skipped

Nonmissing

Numeric value

.S

(S)Skipped

.

Missing

7

YR_IN12

8

Yearly combined household
income^[YR_IN12]

2
3
4
5
6
7
8

DEPND_IN

8

How many people depended on this
income^[DEPND_IN]

Because monthly and yearly income variables were coded in parallel fashion, because
participants typically responded to only one of those variables, and to be conservative about who was
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counted as poor, we created a variable for income category that took the larger value of either monthly or
yearly income.
We obtained a table of US poverty cutoffs from the Census Bureau based on family size (see
Table A9.2).

Table A9.2. Poverty Thresholds for 2013 by Size of Family and Number of Related
Children Under 18 Years
Related children under 18 years
Size of family unit

Weighted
average
thresholds

None

One

One person (unrelated individual).......
Under 65 years..............................
65 years and over...........................

11,888
12,119
11,173

12,119
11,173

Two people......................................
Householder under 65 years...........
Householder 65 years and over........

15,142
15,679
14,095

15,600
14,081

16,057
15,996

Three people....................................
Four people.....................................
Five people......................................
Six people........................................
Seven people...................................
Eight people....................................
Nine people or more..........................
Source: U.S. Census Bureau.

18,552
23,834
28,265
31,925
36,384
40,484
48,065

18,222
24,028
28,977
33,329
38,349
42,890
51,594

18,751
24,421
29,398
33,461
38,588
43,269
51,844

Two

18,769
23,624
28,498
32,771
37,763
42,490
51,154

Three

23,707
27,801
32,110
37,187
41,807
50,575

Four

Five

Six

27,376
31,128
36,115
40,839
49,625

30,545
34,865
39,610
48,317

33,493
38,331
47,134

Seven

Eight or
more

38,006
46,842

45,037

We used the weighted average thresholds from this table as income cutoffs. However, these did
not correspond perfectly with CSBS income categories. We created an approximate crosswalk of Census
thresholds and CSBS yearly household income (see Table A9.3). Persons with a CSBS income category
that was at or below the cutoff category were classified as poor. We again erred on the side of being
conservative, i.e., not classifying a family as poor if most of the values in an income range were above the
poverty threshold for that family size. For example, for one-person families, the poverty threshold was
$11,888, and we linked this with CSBS income category 2. This meant that any CSBS participant
reporting CSBS income categories 1 or 2 (i.e., yearly income below $9,999) and stating that only one
person was dependent on this income would be classified as poor. CSBS participants reporting CSBS
income category 3 (i.e., yearly income of $10,000-$14,999) with one person dependent on this income
would be classified as non-poor, even though some of those persons may have had incomes between
$10,000 and $11,888.
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Table A9.3. Approximate crosswalk of Census poverty thresholds and CSBS yearly
household income, by family size
Size of
family unit
1
2
3
4
5
6
7
8
9

Weighted average
thresholds (dollars)
11,888
15,142
18,552
23,834
28,265
31,925
36,384
40,484
48,065

Highest CSBS income
category beneath the
threshold (approx)
2
3
4
4
5
5
6
6
7

This process permitted us to assign an estimated poverty status, i.e., an individual-level poverty
measure, to each CSBS participant who answered interview questions about monthly or yearly household
income and number of persons who depended on this income. Persons missing any of this information
were excluded from our analyses.
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Appendix 10. Assessing model fit for Aim 3

Table A10.1. Measures of the fit of proportional hazards models of HIV viral suppression among a stratified random
sample of persons newly diagnosed with HIV in New York City in 2006-2012 who were interviewed and followed through
June 2014, by individual and neighborhood characteristics

Variable

108

Perceived
neighborho
od social
cohesion
Age group
(years) at
diagnosis
Sex at
birth
Race/Ethni
city
Country of
birth
HIV
transmissi
on risk
Year of
HIV
diagnosis
Eligible for
treatment
Estimated
poverty
status
Percent of
population
below
federal
poverty
threshold
in past 12
months
Measure of
fit: -2LL
("with

Variabl
e type

Mod
el 1

Model
2

Model
3

Model
4

Model
5

Model
6

Individu
al
Individu
al
Individu
al
Individu
al
Individu
al

Model
7

Model
8

x

x

x

x

x

X

x
x

x

x

x

x

Model
9

Model
10

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x
x

x

X

x

x

x

x

Model
11

Model
12
x

Individu
al
Individu
al

x

Individu
al

x

623

621

Model
15

x

Model
16
x

x

x

x

x

x

x

x

x

x

x

x

X

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

614

614

Neighb
orhood

631

Model
14

X

Individu
al

631

Model
13

618

618

617

x

x

618

617

617

x

x

618

617

614

614

covariates"
)
Compariso
n with
other
model
specified,
using Χ2
Difference
in -2LL
Degrees of
freedom
p-value

N/A

Comp
arison
with
Model
1

Comp
arison
with
Model
1

Comp
arison
with
Model
1

Comp
arison
with
Model
4

Comp
arison
with
Model
5

Comp
arison
with
Model
5

Comp
arison
with
Model
5

Comp
arison
with
Model
5

Comp
arison
with
Model
6

Comp
arison
with
Model
6

Comp
arison
with
Model
11

Comp
arison
with
Model
5

Comp
arison
with
Model
13

Comp
arison
with
Model
13

Comp
arison
with
Model
13

0.553

8.133

10.119

2.912

0.031

0.996

0.084

1.007

0.995

0.086

0.921

4.039

0.576

0.030

0.659

0

1

1

1

1

1

1

1

2

1

1

1

4

1

1

2

N/A

0.457

0.0043

0.0014

0.0879

0.8602

0.3182

0.7719

0.6044

0.3185

0.7693

0.3372

0.4007

0.4478

0.8624

0.7192
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